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1 INTRODUCTION 
 
At present the therapeutic treatment of cancer is strongly limited in its effectiveness due to the 
low selectivity of the drugs used for the cancer modified cells1. It is based on the 
administration of cytotoxic drugs which are highly harmful also for the healthy cells of the 
individual mostly because of their interference with the normal physiology functions. This 
lack of selectivity of anticancer drugs is the cause of their high toxicity in vivo. 
Moreover the unwanted secondary effects are not compensated by a long-lasting remission, 
especially in cases of advanced solid tumors, which still represent an incurable disease with 
survival chances tending, in the long term, to zero. 
The current trend in research on anticancer drugs is to exploit particular traits unique to cancer 
cells. Despite the fact that cancer displays a great heterogeneity in clinical behavior, most 
human tumors share a limited set of acquired capabilities that define the malignant state2. 
These include self–sufficiency in growth signal, insensitivity to antigrowth-signals, avoidance 
of programmed cell death, unlimited replicative potential, sustained angiogenesis, tissue 
invasion and metastasis. Among these hallmarks, the acquisition of unlimited replicative 
potential is a key step to ensure expansive tumor growth. 
The activation of a telomerase maintenance mechanism seems indispensable for 
immortalizing human cells. Telomeres and telomerase, the protein that allows their 
maintenance, have therefore been proposed as preferential targets for anticancer drug 
development. 
 
1.1 Telomeres 
 
In the 1960s, Hayflick and collaborators3 demonstrated that the proliferative capacity of 
normal human somatic cells is finite, and that after a limited number of cell divisions, cells 
stop dividing and enter a state termed senescence. During the past 40 years or more, 
considerable research interest has focused on identifying the mechanism that regulates the 
replicative capacity of normal somatic cells. 
One molecular pathway thought to regulate somatic cell proliferation is that mediated by 
telomeres, specialized DNA-protein structures present at the end of all linear chromosomes4. 
The telomere is a simple sequence of nucleotides together with a group of specific proteins. In 
humans, the sequence TTAGGG is repeated dozens or even thousands of times at each 
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chromosome end. The telomere is involved in several essential biological functions5. It 
prevents chromosomes from recombination, end-to-end fusion and, recognized as damaged 
DNA, it provides a means for complete replication of chromosomes, contributes to the 
functional organization of chromosomes within the nucleus, participates in the regulation of 
gene expression and serves as a molecular clock that controls the replicative capacity of 
human cells and their entry into senescence6. In particular, the replication of chromosome 
ends pose a special problem for the cells. In fact the DNA is progressively lost from the ends 
of chromosome each time cell divides, because the conventional DNA polymerase is not fully 
able to replicate the 3’-end of the lagging strands of the linear  molecule. This “end replication 
problem” leaves a gap between the final priming events and the end of chromosomes7,8. 
Without an appropriate mechanism to offset telomere shortening, normal human cells 
proliferate for a certain number of divisions (the Hayflick limits), followed by an irreversible 
growth arrest phenomenon known as cellular senescence9,10. Rare survivor cells are able to 
maintain telomere length. In normal mammalian cells, one well-characterized mechanism of 
telomere maintenance and elongation is mediated by the enzyme telomerase11.  
 
1.2 Telomerase 
 
Telomerase is a RNA-dependent DNA-polymerase that can add the hexameric repeats, 
TTAGGG, to chromosome ends, extending and maintaining the length of the telomeres and 
thereby extending the number of divisions the cell may undergo12.  
It is a unique reverse transcriptase composed of both protein subunits (among which the 
catalytic subunit hTERT in humans with reverse transcriptase activity)13 and a RNA 
component (hTR in human) 14  that serves as the template for the addition of the repeated 
sequence to 3’-chromosome ends15. hTR is highly expressed in all tissue regardless of 
telomerase activity16, with cancer cells generally having fivefold-higher expression than 
normal cells. In contrast, the expression of the human catalytic component hTERT is 
estimated at less than 1 to 5 copies per cell17. hTERT is generally repressed in normal cells 
and upregulated in immortal cells, suggesting that hTERT is the rate-limiting component of 
the telomerase enzyme and its activity18.  
The advent of a highly sensitive telomere repeat amplification protocol (TRAP assay) allowed 
the screening of a variety of human tumors19. The TRAP assay allowed the evaluation of 
telomerase activity of normal human tissues and of a whole spectrum of human tumors20. In 
normal human cells, telomerase activity appears to be strictly regulated during development. 
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Its activity is extinguished during embryonic differentiation and so most somatic cells are 
devoid of telomerase activity after birth, but remain active in some tissue, such as male germ 
cells, activated lymphocytes, and certain types of stem cell population21. A low level of 
telomerase activity continues to express in some specific proliferating epithelial cells found in 
the breast, endometrial tissues, the basal layer of the skin including hair follicles22-25. This 
telomerase activity is reactivated in 85-90% of diverse human tumors20 while adjacent healthy 
tissue is typically telomerase-negative.  
Therefore, the evidence that most cancer cells activate telomerase whereas normal cells are 
usually devoid of telomerase activity has naturally led to extensive investigations in order to 
detect this protein and its activity for a potential use in cancer diagnosis and prognosis and to 
eventually monitor the tumor response to therapy. Finally, these data have greatly inspired the 
development of various strategies to target telomere and telomerase for cancer therapy. 
 
1.3 Telomerase as target of cancer therapy. 
 
The target of anti-telomerase drugs can principally be the catalytic subunit hTERT and the 
RNA subunit hTR, or the regulation of the expression of telomerase and its associated 
proteins26. 
Targeting the hTERT catalytic subunit, various nucleoside or non-nucleoside reverse 
transcriptase inhibitors are under investigation, and these represent interesting candidates for 
clinical drug development. Nucleoside analogues such as 3’-azido-3’deoxythymidine 1 (AZT) 
are small molecules with reverse transcriptase inhibitors effect.  
     
These types of molecules block the incorporation of dNTPs into the neosynthesized DNA 
during the reverse transcription activity. In early studies, AZT was able to partially reduce the 
telomerase activity, but the cells showed only some weak proliferative impairment. This 
compound with other nucleoside analogues showed a stronger inhibitory effect27, but there is 
O
HN3
HH
HH
HO
N
NH
O
O
1 
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an indirect effect such as the incorporation of the nucleoside analogs into mitochondrial DNA 
causing the depletion of mtDNA and mitochondrial toxicity. 
Non-nucleoside inhibitors are compounds that inhibit the telomerase by binding the active site 
of telomerase, but they do not have effect on other DNA and RNA polymerases. These small 
molecules cause progressive telomere shortening in pharmacological screening programs. 
One of the most promising molecules is probably the BIBR 1532, which is a very specific 
drug and non-competitive inhibitor of telomerase enzyme, suggesting that the binding site is 
different from DNA primer and nucleotide binding site28. It leads to progressive telomere 
shortening, followed by a senescence-like growth arrest, and further induces a significant 
decrease of the tumorigenic potential in vivo. 
Targeting the RNA hTR is a strategy that aims at blocking the access of telomerase to its 
template RNA resulting in inhibition of telomerase activity. Another promising approach is to 
employ mutant hTRs that introduce mutations into the telomeres indirectly impairing the 
structure of telomeres.  
Targeting directly the element that seems to force cells into crisis, i.e. the length of telomeres, 
has largely enriched the development of anticancer candidates. Emerging evidence suggests it 
is the shortest telomeres rather than average telomere length that cause chromosome end 
fusions and apoptosis in telomerase inhibited cells29, even if it is still not fully known what 
mechanism and molecular actors are implicated in the telomere dysfunction related cell crisis.  
However, the testing of inhibitor compounds has shown that the time required for the 
shortening of the telomere to the critical length is too long to contrast the progression of 
tumors, especially in cases of advanced solid tumors30. 
A different approach that we envisaged is to exploit the activity of telomerase instead of 
inhibiting it, using a specific molecule, a prodrug that can be activated only in tumor tissues. 
 
1.4 Prodrug strategies. 
 
 
In recent years attempts have been made to administrate drugs as prodrugs31-34. From a 
therapeutic point of view, a prodrug is an inactive compound, which can be transformed in 
vivo into an active drug, i.e. into a therapeutically active compound, thanks to a chemical or 
an enzymatic transformation of its structure. Normally, in a prodrug, the active agent is linked 
to a carrier (also known as a promoiety), and the activation occurs by hydrolysis, oxidation or 
reduction. However, there are prodrugs that do not contain a promoiety and are equally 
activated by oxidation, reduction or other chemical reaction33. 
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Normally prodrugs can be designed to overcome pharmaceutical, pharmacokinetic, or 
pharmacodynamic barriers such as insufficient chemical stability, poor solubility, insufficient 
oral absorption, inadequate blood-brain barrier permeability, irritation or pain, toxicity and 
also unacceptable taste or odor. A developing field of high importance is that of rationally 
designed prodrugs for tissue or cell targeting. 
Among the objectives of prodrug design the improvement bioavailability is one of the most 
important. There are a variety of factors limiting bioavailability: aqueous solubility, passive 
intestinal absorption and targeted active absorption. 
Inadequate aqueous solubility is an important factor limiting parenteral, percutaneous and oral 
bioavailability. Charged promoieties (e.g. phosphates, hemisuccinates, aminoacyl conjugate) 
and neutral promoieties (e.g. polyethylen glicols, PEG) can be used in order to overcome the 
problem. Two examples of this kind of prodrugs, PEG-taclitaxel and fosphenytoin, are 
showen in Figure 1. Improved aqueous solubility for better administration has been 
demonstrated for the taxol derivate PEG-taclitaxel35. Fosphenytoin is a hydrophilic phosphate 
prodrug of the anticonvulsant phenyton and is hydrolyzed rapidly by phosphatases36.  
 
O OH
O
O
O
AcO
O
Ph
O
H
HO
OPh
NHPh
O
O
O
O
PEG
O
PEG-paclitaxel
N
N
H
O
O Ph
Ph
O
P
O
HO
HO
fosphenytoin  
Figure 1. Examples of promoietis for improved aqueous solubility 
 
To increase passive intestinal absorption a prodrug strategy is often adopted . Various esters 
of carboxylic acids, a frequently encountered group of carried-linked prodrugs, are cleaved by 
hydrolysis, enzymatic and/or chemical, to liberate the active compound37. There are many 
examples such as the ACE inhibitors benazepril and fosinopril, the statin lovastatin, and some 
antibiotics such as pivampicillin (Figure 2)32. 
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Figure 2. Examples of  ester prodrugs showing improved passive intestinal absorption. 
 
Some prodrugs use carrier-mediated transport to increase intestinal absorption. For example 
valacyclovir and valganciclovir (Figure 3), the valine esters of acyclovir (ACV) and 
ganciclovir (GCV), show an bioavailability 5 times higher than that of acyclovir. This is due 
to transport by the intestinal dipeptide transporter PEPT134. 
 
N
NHN
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O
H2N
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Valaciclovir Valganciclovir
 
Figure 3.  Examples of prodrugs utilizing oligopeptide transporters. 
 
Finally an additional prodrug strategy relies on the organ – or tissue-selective delivery of a 
drug33. Rationally designed tissue targeting is probably the most exciting objective of a 
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prodrug strategy. This can be achieved by passive enrichment in the target tissue, targeting 
specific transporters, targeting surface antigenes and targeting tissue- or cell specific enzyme.  
Examples of passive enrichment in target tissue are cytostatic and cytotoxic agents conjugated 
to PEG with MW > 50000 (e.g. PEG-paclitaxel, Figure 1). They are reported to exhibit an 
improved therapeutic efficacy due to their longer half-life and selective accumulation in 
tumors cells. This passive tumor targeting is called the “enhanced permeability and retention” 
(EPR) effect, and its mechanism is not fully understood. The low drug load achievable by 
such macromolecular conjugates requires more potently cytotoxic agents than traditional 
anticancer drugs. 
The number of examples of prodrugs targeting tissue-specific transporters is relatively 
limited. Levodopa constitutes an example of enrichment resulting from active import of the 
prodrug into the brain followed by tissue entrapment of the active metabolite 
dopamine(Figure 4).38 It is a substrate for the neutral amino acid transporters present at the 
blood-brain barrier. After brain entry, levodopa is decarboxylated to dopamine, which can act 
locally, being no longer a substrate for the neutral amino acid transporter. 
HO
OH
OH
O
NH2
HO
OH
NH2
dopaminelevodopa  
Figure 4. Example of prodrugs targeting the brain. 
 
There are many examples of prodrug activated from tissue- or cell-specific enzyme. Specific 
targeting of virus-infected cell is elegantly realized by the antiviral prodrug acyclovir and all 
other selective antimetabolites used as antiviral agents. The activity of such antimetabolites 
implies their intracellular phosphorylation by kinases to form a nucleotide analogue that 
inhibits DNA synthesis. The selective antimetabolites are phosphorylated only by kinases 
coded by the viral genome and expressed in infected cells. As a result, acyclovir and all other 
selective antimetabolites are active only in infected cells39. 
The selective delivery of cytotoxic drugs to tumor cells, without concomitant damage to 
normal tissues, is a major challenge in cancer chemotherapy. Prodrugs for active tumor 
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targeting are therefore of high interest. Tumor specificity can be achieved by targeting 
trasporter system or enzyme having a higher activity in tumor cells.  
Prodrugs of cytotoxins have been used in cancer therapy for some time (e.g. araC esters40, 
cyclophosphamide41), but they undergo a non-specific activation and are primarily used to 
modify drug uptake or pharmacokinetics by controlling physicochemical properties.  
Capecitabine, an orally available triple prodrug of 5-fluorouracil (5-FU), offers a good 
example of a prodrug activated by tumor specific enzyme42. It is well absorbed orally and 
undergoes three activation steps resulting in high concentration of the active drug in tumor. It 
is first hydrolyzed by liver carboxylesterase, the resulting metabolite being a carbamic acid 
which spontaneously decarboxylates to 5’-deoxy-5-fluorocytidine (Figure 5). The enzyme 
cytidine deaminase, which is present in liver and tumor, then transforms 5’-deoxy-5-
fluorocytidine in 5’-deoxy-5-fluorouridine. Transformation into 5-FU is catalyzed by 
thymidine phosphorylase and occurs selectively in tumor cells. 
O
OHOH
H3C
N
NH
HN
O
F
O
O
carboxylesterase
(liver)
O
OHOH
H3C
N
NH
HN
O
F
O
OH
CO2
O
OHOH
H3C
N
NH
NH2
O
F
Cytidine deaminase
(liver and tumor)
O
OHOH
H3C
N
NH
O
O
F
Thymidine
phosphorilase
(tumor)N
H
NH
O
O
F
5-fluorouracil
5'-deoxy-5-fluorouridine 5'deoxy-5-fluorocytidine
Capecitabine
 
Figure 5. The stepwise activation of capecitabine to the antitumor drug 5-fluorouracil. 
 
Another example of prodrug activated from specific enzyme is Leu-doxorubicin (Figure 6). It 
was first studied in human ovarian cancer cell xenografts in mice showing conversion to 
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doxorubicin in tumor cells by cathepsin-like enzyme, resulting in superior antitumor activity 
than with doxorubicin itself. The role of the conjugated aminoacid in this prodrug is not to 
physically locate the prodrug on tumor cells, but to serve as a substrate for designated 
enzymes that are produced and secreted preferentially by tumor cells. The prodrug gave lower 
levels of the cardiotoxic doxorubicin in heart tissue. 
O
O
OH
OH
COCH2OH
OH
O
O
H3C
OH
HN
O
OH
Leu-doxorubicine  
Figure 6.  Strutture of leu-doxorubicine. 
 
Regardless of the mechanism of prodrug selective activation, it is useful to consider an 
anticancer prodrug as comprised of three distinct domains: trigger and effector units joined by 
a linker43,44 (Figure 7). The role of the trigger unit is to undergo efficient metabolism by 
tumor-specific mechanism. The role of the linker is to deactivate the prodrug up to the trigger 
metabolism. The role of the effector is to kill cells rapidly. 
 
TRIGGER LINKER EFFECTOR
 
         Figure 7. Schematic structure of a prodrug 
 
In the case of prodrug activated by a specific enzyme, the trigger must be recognized from its 
catalytic portion. For this reason, it must have a structure similar to a physiological substrate 
of enzyme. Moreover, the effector must not interfere with the catalytic portion of the enzyme. 
In the last example, doxorubicin prodrug (Figure 6), the trigger is the aminoacid leucine, the 
linker is the peptide bond and the effector is doxorubicin. 
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Another important characteristic of a prodrug is its in vivo stability, since it must be able to 
reach the specific site, the tumor cells, without degradation in the blood or in the intracellular 
space. In addition, it must be able to cross the cellular membrane. For this reason it must be 
small and lipophilic or able to use an active transport present in the cellular membrane. 
Using this approach, several clinically successful prodrugs have been developed; however, 
few prodrugs developed show tumor selectivity. This can be rationalized by the fact that, 
unlike bacteria and viruses, cancer cells do not contain molecular targets that are completely 
foreign to the host33. Therefore it seems necessary to exploit phenotypic differences between 
normal and tumor cells, especially the presence of enzymes that may activate prodrugs. 
Enzymes which can be used for local activation of prodrugs include tyrosinase, thymidylate 
synthase, thymidine phosphorilase for example, but also telomerase. 
 
1.5 Prodrugs activated by telomerase. 
 
 
As outlined above, the structure of prodrugs activated by telomerase must have some specific 
characteristic: 
• it must obviously be a telomerase substrate; 
• it must be stable to enzymatic attack in the blood and in the intercellular media; 
• it must be selective to telomerase respect to DNA polymerases, since otherwise it loses 
selectivity to cancer cells; 
• it must be able to release a cytotoxic compound into the cells. 
 
The physiological telomerase’s substrates are the 2’deoxynucelotide-5’-triphosphates dGTP, 
dATP and TTP, because telomerase adds thousands of hexameric repeats TTAGGG at the end 
of the telomere. The catalytic site of telomerase recognizes the nucleotide triphosphate, adds 
the nucleotide monophosphate into the telomere, freeing a molecule of pyrophosphate. The 
structure of the prodrug should therefore be similar to a dNTP, but with a cytotoxic group in 
the γ position (Figure 8): the TS group is the telomerase’s substrate, while the CT moiety is 
the cytotoxic compound. 
O P O
O
O-
P
O
O-
O P
O
O-
O TSαβγ
2
CT
 
       Figure 8 Schematic structure of telomerase-activated prodrugs. 
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Both TS and CT should be nucleosides or nucleoside analogues. The TS groups can be chosen 
among the physiological substrates of telomerase: deoxyguanosine, deoxyadenosine and 
thymidine (Figure 11). As to the candidates for CT moiety, it is possible to choose between 
the cytotoxic nucleoside analogues used as anticancer (e.g. arabinocytosine AraC, etc.) or 
antiviral (e.g. acyclovir ACV, ganciclovir GCV, etc.) drugs (Figure 12). 
A prodrug with the structure 2 is similar to a dinucleotide oligophosphate. The dinucleotide 
oligophosphates (DNOPs) are ubiquitous compounds formed by two nucleotides bridged by 
two to seven phosphates. The most widely investigated are diadenosine polyphosphates 
(ApnA) and diguanosine polyphosphates (GpnG) (Figure 9). They are natural compounds and 
some of them, in particularly diadenosine oligophosphates, are involved in extracellular and 
intracellular signaling.45 Extracellular diadenosine oligophosphates are involved in blood 
pressure regulation, stimulation of DNA synthesis in cells and in many aspects of messenger 
RNA metabolism46. 
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Figure 9.  Structures of adenosine oligophosphates and guanosine oligophosphates. 
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They are stable in vivo, unlike NTPs and dNTPs that are rapidly dephosphorylated in 
intercellular media and during their diffusion into cells. Thus, molecules with a structure 
similar to the DNOPs are very likely to be stable in the blood and in intercellular media47. For 
this reason many DNOPs are studied as potential drugs  and they are used as probes to the 
active sites of enzymes in which nucleosides and/or nucleotides are involved in phosphate 
transfer reactions48-52. Some examples of non-natural DNOPs are shown in figure 10. 
O
OH
OPO
O
O-
O P O
O-
O
O OH
P
O-
O
3
N
N
N
NH2
N
OH
OH
Ap5T
O
OH
OPO
O
O-
O P O
O-
O
O OH
P
O-
O
2OH
OH
Up4U
N
N
NH2
O
NH
N
O
O
NH
N
O
O
 
Figure 10. Example of non-natural DNOPs. 
 
The DNOP Ap5T is a good inhibitor of thymidine kinase and thymidilate kinase, two 
enzymes that are elevated in malignancy and are essential to DNA synthesis50,53. 
Diuridine tetraphosphate Up4U has shown to have beneficial properties in the treatment of 
variuos diseases. It is a potent and selective agonist of P2Y receptor. It has demonstrated to 
facilitate the clearance of mucous secretion from the lungs in subject needing therapy for 
various diseases (e.g. cystic fibrosis, chronic bronchitis, asthma, bronchiectasis, post operative 
mucous retention and other diseases that involve mucus secretion).54,55 
It is not clear if DNOPs are able to be uptaken from cells for their high charge, but nucleotide 
triphosphates with substituent groups in γ position increase the retardation factor (Rf) on thin 
layer chromatography (TLC), showing that the substitution increases the lypophilicity  of the 
molecules15,56.  
The presence of a group in the γ position probably increases the selectivity towards 
telomerase at the expenses of DNA polymerase. In fact it is known that the presence of a 
group bound to the γ-phosphate increases the selectivity towards reverse transcriptase of HIV, 
  15
which has a very similar activity to telomerase, becoming at the same time a bad substrate for 
DNA-polymerase α, β.  
In a molecule with the structure 2 the TS groups may be recognized from telomerase and the 
telomerase should add the TS groups into the telomere, freeing the cytotoxic fragment as a 
diphosphate. This fragment can play a cytotoxic function in this form (e.g. arabinocytosine-
diphosphate, AraCDP, is a inhibitors ribonucleotide reductase, RNR), or can be transformed 
from kinases into a triphosphate and incorporated into DNA by DNA polymerase (e.g. if CT 
is acyclovir or dideoxycytidine). 
In order to verify these hypotheses, a library of different molecules with the general structure 
2 has been synthesized using different TS and CT groups. As TS groups the physiological 
substrate of telomerase (dA, dG and T) and inhibitors of telomerase (AZT) were chosen; as 
CT groups acyclovir (ACV), dideoxycytidine (ddC), ganciclovir (GCV) arabinocytidine or  
(AraC) and 3’-O-nitro-2’-deoxycytidine (Nitro-C) were chosen. ACV, GCV and ddC are 
the chain terminator used in antiviral therapy39, while AraC is an antimetabolite agent57.  
Nitro-C is a new antimetabolite agent that is a chain terminator but also able to release the 
NO radical specie inside the cells. This radical can damage the DNA chain, then killing the 
host cell. Nitro-C, as 5’-monophosphate,  could act as an irreversible inhibitor of thymidilate 
synthase, whereas the triphosphate could serve as an unnatural substrate for, or inhibitor of, 
DNA polymerase to elicit a cytotoxic anticancer/antiviral effect58. 
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Figure 11. Telomerase substrates (TS). 
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Figure 12. Cytotoxic compounds. 
 
An attempt has also been made to prepare analogues to dinucleosides triphosphate 3, where 
the β-phosphate is replaced by a phosphonate or alkyl- aryl-phosphonate in order to remove a 
negative charge in the phosphate bridge, to increase the molecular hydrophobicity, and to test 
how this set of molecules can cross the cell membrane. 
TSOP
O
O
CT O P
O
O
O P O
O
R
R = CH3, Ph, OCH3, OPh
3
α β γ
 
          Figure 13. Schematic structure of β-phosphonates. 
 
The replacement of a phosphate group with a phosphonate group (R = CH3 or Ph) or alkyl- 
aryl-phosphate group (R = OCH3 or OPh) in α, β or γ position in dNTPs or NTPs has already 
been used to increase molecular stability to the dephosphorilation or to increase molecular 
selectivity in case of a particular enzyme (HIV reverse transcriptase versus DNA 
polymerase)56. However, the structure of these molecules provides either a γ-positioned 
phosphonate59 or the presence of a  β,γ –positioned methylendiphosphonate unit56 (Figure 14).  
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Figure 14. Example of phosphonate. 
 
In our case the phosphonate units must replace the phosphate in β-position, because this is the 
less sensible position for the action of telomerase and DNA polymerase enzyme. In fact the 
phosphate in γ-position is the one to be incorporated, together with the base, into the telomere, 
while the phosphate in α-position is the one that should be recognized by DNA polymerase 
and incorporated in DNA chain, thus carrying out its cytotoxic activity. The presence of a 
substituent in one of these positions would make the phosphate hardly usable by these two 
enzymes.  
The molecules prepared were tested on cellular cultures of different cancer cell lines and a 
healthy cell line. The most efficient compounds were then tested on mice.  
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2 SYNTHESIS OF NEW DINUCLEOTIDE TRIPHOSPHATES 
 
2.1 General considerations 
 
Dinucleotide triphosphates, as nucleotide triphosphates, are difficult to make, isolate and 
characterize60 due to several factors. Firstly, many of the methods for their preparation 
involve combinations of charged ionic reagents with more lipophilic substrates (e.g. 
orthophosphates and protected nucleosides). Consequently, it is difficult to find appropriate 
reaction media and the purification procedures must involve isolation of a charged water-
soluble product from a mixture of hydrophilic and hydrophobic impurities. Secondly, these 
compounds, and especially their intermediates (e.g. nucleotide diphosphate), are not 
particularly robust. It is difficult to make quantitative generalizations about their 
decomposition rates, but it is certain that the hydrolysis of these compounds is accelerated 
under both basic and acidic conditions. 
Their isolation protocols involve gravity chromatography of the crude product on DEAE-
cellulose [(diethylamino)ethylcellulose] using a gradient of increasing volatile protic 
ammonium salt in water (e.g. triethylammonium bicarbonate) as eluant. 
31P-NMR spectra of dinucleotide triphosphates feature two resonances at around -11 ppm (the 
α and γ phosphorus atoms) and a resonance at about -22 ppm (the β phosphorus atom). 
Chemical shift values for these kinds of molecules are highly pH and counter ion dependent. 
The ease with which these signals are observed is inversely related to the exchange processes 
that occur on the NMR time scale. These exchange processes, usually involving the 
triphosphate counter ions, can be slowed down by buffering the medium. The coupling 
constant between the two geminal phosphorus atoms is about 19Hz. 
Proton NMR spectra of dinucleoside triphosphates are also influenced by exchange 
phenomena. Moreover, inadequate freeze-drying can result in trialkylammonium salt 
impurities that can obscure and/or overshadow relevant peaks in the spectra. The spectral 
characteristic of these compounds are also influenced by pH. 
 
2.2 Synthetic pathway 
 
The most widely used synthesis of dinucleoside triphosphates involves the disconnection 
shown in Figure 15. Only the nucleoside monophosphate 5, the orthophosphate 9 and the 
cytotoxic compound 11 are commercially available. All the other compounds need to be 
prepared. 
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Figure 15. Retrosynthetic pathway of dinucleotide triphosphates. 
 
The dinucleotide triphosphates preparation is carried out by coupling the two phosphates 5 
and 7. This coupling is made by activating one of the two phosphates (in our case 7) and by 
letting it react with the other nucleotide. 
There are two ways in which nucleotide phosphates are transformed into activated compound 
6. The most common methods use 1,1’-carbonyldiimidazole (CDI) or morpholine or 
piperidine to transform the nucleotide phosphate into a nucleotide-5’-phosphoramidate61 
(Figure 16). This intermediate is not isolated but is coupled with a second nucleotide at room 
temperature. The phosphoramidate derivates have frequently been utilized as useful 
intermediates in the coupling of phosphates groups60. 
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Figure 16. Activation of a nucleotide phosphate in coupling reactions with phosphorammidate method. 
 
 
Another method consists in the activating of the phosphate by reaction with diphenyl 
chlorophosphate, thus forming an intermediate 6 whose terminal phosphate can be easily 
replaced by the monophosphate 5 (figure 17). 
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Figure 17.  Activation of a nucleotide phosphate in coupling reactions with diphenyl chlorophosphate. 
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The yield is always low with both methods and never exceeds 50%. The most frequent 
method in litterature has therefore been used, employing CDI as reagent in order to activate 
diphosphate 7 to phosphoramidate 6, since it generally yields more61. 
Using the same activation methods it is possible to obtain the diphosphate 7 from 
monophosphate 10 and orthophosphate 9. 
Monophosphate nucleotides 10 are not often available, especially in case of modified 
nucleotides and, when their synthesis is required. According to a common procedure, 
phosphorus oxychloride (POCl3) is used with a polar solvent, such as trimethylphosphate o 
triethylphosphate, and is then hydrolyzed to form a monophosphate nucleotide. This 
procedure was first used by Yoshikawa and co-workers who also discovered that the 
phosphorylation rate of nucleosides was accelerated by using trimethyl- or triethylphosphate 
as solvent62. This method is practically the only way used to prepare nucleoside 
monophosphate, because this monophosphorylation is selective for the 5’-hydroxyl group of 
the sugar moiety in unprotected nucleosides (Figure 18). 
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        Figure 18. Monosphosphates synthesis. 
 
The major difficulties of the above mentioned reactions lie in the preparation of reagents and 
in the purification of the reaction’s results. Phosphates are too polar compounds to be 
solubilized in usual organic solvents (e.g. dimethylformamide), whereas this would be 
required in order for the reaction to take place. The most common way to overcome the 
problem is to transform the phosphate into its tributylammonium salt: the ionic pair 
phosphato-tributylammonium is now soluble in DMF and therefore enables a reaction.  
This transformation is made possible by first converting the sodium phosphate salt into the 
pyridinium salt by chromatography on cationic exchange polystyrenic resin in pyridinium 
form (eluant water:methanol 1:1). The solution, reduced to small volume, is then treated with 
1 mol equiv of tributylamine/mol of phosphorus. At the end of this procedure, it is necessary 
to completely remove the water from the tributylammonium salt, before starting a new 
reaction. Water can in fact react with phosphoramidate to give the deactivated reagent (Figure 
19). 
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Coevaporation with anhydrous pyridine and anhydrous dimethylformamide is usually 
necessary to remove all water. In order to increase the anhydricity of the reaction condition 
we have also used molecular sieves in the reaction’s flask both for diphosphates and 
triphosphate synthesis. 
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Figure 19.  Reaction of phosphoroamidate in presence of water. 
 
 
2.3 3’-O-nitro-2’-deoxycytidine 
 
This non conventional nucleoside analogue is not commercially available. It has therefore 
been prepared using a known procedure58. The nucleoside analogue was prepared in five steps 
starting from 2’-deoxyuridine 12 (Figure 20). The 2,3’-anhydro-5’-O-benzoyl-2’-
deoxyuridine 13 was prepared by a one-pot tandem Mitsunobu reaction, using 
triphenylphosphine, diisopropyl azodicarboxylate and benzoic acid in 82% yield. The ring 
was opened with ammonium nitrate in DMF to form the O-nitrate esters 14 in 25% yield 
which was then reacted with 1,2,4-triazole and 4-chlorophenyl dichlorophosphate in pyridine 
to afford the corresponding 4-(1,2,4,-triazolo) derivate 15 in 72% yield. Subsequent treatment 
of 15 with aqueous ammonia in dioxane yielded the 5’-O-benzoyl-3’-O-nitro-2’-
deoxycytidine 16 (53%), which on deprotection with NaOMe in methanol afforded the target 
3’-O-nitro-2’-deoxycytidine 17 in 63% yield. 
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Figure 20. Synthesis of 3’-O-nitro-2’-deoxycytosine. 
 
2.4 Monophosphates synthesis 
 
The first synthetic targets were the monophosphate compounds. Different compounds, both 
nucleosidic and non-nucleosidic, have been used for the implementation of the 
monophosphates synthesis and their purification. 
Aiming at studying the monophosphatation of acyclovir, 2-benzyloxy-ethanol 18 and 2-((1H-
benzo[d]imidazol-1-yl)methoxy)ethanol 19 have been used as starting substrates, in order to 
establish reaction conditions and in particular purification methods. The synthesis of 19 was 
performed as reported from Yavorskii and co-workes63. The synthesis of monophosphates 
with phosphorus oxychloride  and the above mentioned substrates has been made at 0°C in 
diethyl ether or THF, which turns out to be better for the solubilization of reagents, and the 
work-up has been made using a solution of NaHCO3.  
A first purification of the monophosphate 18, made by DEAE-cellulose chromatography, 
allowed the recovery of some fractions containing the desired monophosphate contaminated 
by ortophosphoric salt, which was eliminated as barium salt precipitation from water/ethanol 
solution adding BaCl2. 
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The monophosphatation reaction of nucleosides analogues (ACV, AZT, ddC, araC and 
GCV) have been performed using  PO(OEt)3 as solvent. The work-up has been made using 
NaHCO3 (acquous, 5%) and than adjusting to pH 7 with NaOH 1M. The purification method 
with barium salt cannot be used for nucleosides. These compounds precipitate as barium salt 
together with orthophosphate. Therefore, in order to obtain a proper purification in these 
cases, the operation must be repeated twice through DEAE-cellulose. 
This monophorilation method presents a disadvantage that is not enough mentioned in the 
literature: the formation of a phosphoric diester 20 resulting from the double reaction of 
nucleoside with POCl3. 
 
 
                  Figure 21.  Phosphoric diester 
 
Even though the reaction is carried out at 0°C by adding a nucleotide to an excess of POCl3 in 
triethylphosphate, the substition reaction to the phosphorus oxychloride has a speed similar to 
that of the monosubstituted intermediate. In order to solve this problem the reaction was 
performed at -10°C, with a lower concentration of reagents. Thus, the formation of the by-
product was minimized. 
Using this standard procedure a library of nucleoside monophosphate not commercially 
available has been prepared (Table 1). 
The preparation of ganciclovir monophosphate (GCVMP) required the protection of one of 
the hydroxyl groups before performing the reaction with POCl3 in order to prevent the 
diphosphorilation. The protection was performed with acetate group. The mono-O-acetate 
ester of ganciclovir 22 was prepared by reaction of ganciclovir with an excess of trimethyl 
orthoacetate followed by acidic hydrolysis of the cyclic orthoester 21 intermediate64 (Figure 
22). 
NH
N
N
O
NH2N
OHO
HO
NH
N
N
O
NH2N
OO
O
H3CO
NH
N
N
O
NH2N
OHO
O
O
CH3C(OCH3)3
TFA, DMF, rt
2h
H2O, overnight
GCV 21 22
 
Figure 22. Selective monoprotection of ganciclovir. 
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Table 1. Library of monophosphate. 
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2.5 Nucleotide diphosphate’s synthesis. 
 
The most common ways to prepare a nucleotide diphosphate are principally two: either the 
phosphorylation of its monophosphate with tributylammonium orthophosphate in the 
presence of carbonyldiimidazole (CDI)65 or the direct diphosphorylation of nucleosides with 
tributylammonium pyrophosphate in the presence of dicyclohexilcarbodiimide66. The direct 
diphosphorylation approach was tried for the preparation of ACVDP, but no product was 
recovered from the reaction mixture. Hence for the preparation of every diphosphate a two 
steps procedure adapted from Hoard and Ott65 was used. The monophosphate was first 
transformed into the tributyl ammonium salt as described above. The tributylammonium 
orthophosphate necessary for the reaction was generated from reaction between anhydrous 
orthophosphoric acid and tributylammine. Than the two compounds were coupled in presence 
of CDI (Figure 23). 
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Figure 23.  Nucleotide diphosphate’s synthesis. 
 
Using this procedure we have the formation of the imidazolidate 27 from a nucleotide 
monophosphate 26 and excess 1,1’-carbonyldiimidazole (CDI). The reaction is complete in 
about 2 hours at room temperature. Unreacted CDI is decomposed with methanol, before 
tributylammonium orthophosphate is added, to eliminate formation and subsequent necessity 
for separation of inorganic polyphosphate. Using an excess of orthophosphate the 
precipitation of imidazolium orthophosphates has taken place. The phosphorylation is 
essentially complete within 16 hours, and the product is purified by anion-exchange 
chromatography on DEAE-cellulose. 
Results obtained with various monophosphates are given in Table 2. The transformation of 
the nitro-cytosine monophosphate 25 and ganciclovir monophosphate GCVMP into 
diphosphate did not take place. These results are not very clear. In the case of GCVMP we 
found that during the work-up the acetate group was last and the free hydroxyl group could 
probably interfere during the coupling reaction.  
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Table 2.  Library of diphosphates. 
 
 
 
2.6 Dinucleotide triphosphate synthesis. 
 
The preparation of dinucleotides was performed with a  procedure similar to that used for the 
preparation of nucleotide diphosphates. The phosphoroimidazolidates resulting from 
activation of nucleoside diphosphates with CDI were coupled with an excess of nucleoside 
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monophosphate commercially available. Both the nucleotide diphosphate and nucleotide 
monophosphate were first transformed in the tributylammonium salts using standard 
procedure.  
Also in this case the reaction was performed in 16 hours and the yields ranged between 30% 
and 60%. 
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Figure 24. Synthesis of DNOPs. 
 
The library of  eight different dinucleotide triphosphates reported in Table 3 was prepared 
using these procedure. As TS group 2’-deoxycytidine was also used. This nucleoside is the 
only deoxynucleotide not used from telomerase. The synthesis of a dinucleotide triphosphate 
with this moiety instead of a telomerase substrate was necessary to verify the prodrug’s 
activity mechanism. 
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Table 3. Library of triphosphates. 
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2.7 Synthesis of β-Phosphonates 
 
The synthesis of dinucleotide triphosphate analogues with a phosphonate in β position has 
proved to be difficult, because of the lower reactivity of the phosphonate in comparison with 
normal phosphate in the coupling processes. 
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Figure 25.  Phosphonate’s synthesis. 
 
At first we used a modified procedure by Alexandrova56 (Figure 25), according to which 
methylphosphonic dichloride was activated with triazole .The first tributylammonium salt of 
monophosphate nucleotide was added to the solution of methylphosphonic bis(1,2,4-
triazolide), followed after 1 hour by the second nucleotide. Unfortunately the reaction was not 
successful and stopped at the first substitution. 
In a second attempt the β-phosphonate nucleoside was again activated with CDI and the 
second nucleoside added, but again no coupled product was obtained.  
Believing that the intermediate β-phosphonate has a low reactivity towards a substitution 
reaction with phosphate, we then activated the monophosphate nucleoside with CDI and used 
the phosphonate as nucleophile. Unfortunately the result was not successful again. The above 
mentioned attempts showed a low reactivity of a phosphonate, both as electrophile and as 
nucleophile. Also changing methylphosphonic dichloride with phenylphosphonic dichloride  
did not lead to any positive result. 
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Figure 26.  Different strategy for phosphate’s synthesis. 
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3 EVALUATION OF PRODRUGS ACTIVITY IN VITRO 
3.1 General considerations 
 
Every compound prepared was then evaluated for growth inhibitory activity against different 
cancer cell lines using different methods: viability and proliferation methods.  
Cell viability, related to cell activity, was evaluated measuring the ATP present in the cell by 
a spectrophotometic analysis. High level of ATP means high cell viability.  
Cell proliferation was evaluated measuring the bromo-deoxyuridine incorporated in DNA. 
High quantity of BrdU incorporated during the DNA synthesis means high proliferation 
activity. 
The tests were performed using two different protocols. As shown in Table 4, according to 
protocol A, the addition of prodrug was done two days after cells seeding and the activity 
measurement after five days. In protocol B the addition and measurement were performed 
after one day and two days respectively. 
 
Day 0 1 2 3 4 5 
Protocol A S  A   M 
Protocol B S A M    
         Table 4. Protocol used in cell test. S = Cells seeding; A = Prodrug addiction; M = Measurement. 
 
 
3.2 Studies on cytotoxic activity of the prodrugs ACV-TP-TS 
 
The first prodrug used to measure the cytotoxic activity toward cancer cells was the ACV-
TP-dG. A preliminary test of this prodrug candidate (using protocol A on colo-rectal 
carcinoma cell line SW620) showed a lower growth of treated cancer cells (Figure 27) in 
comparison to the control colture (Figure 28).  
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      Figure 27. SW620 colo-rectal carcinoma cells 
        tested with ACV-TP-dG 
                                
        Figure 28. SW620 colo-rectal carcinoma cells . 
 
The same ACV-TP-dG was then tested using protocol A once again and measuring the 
viability at different concentration of prodrug on different cancer colo-rectal carcinoma cell 
lines. These kind of cells were chosen because colo-rectal carcinoma cell lines have generally 
high telomerase activity.  
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  Figure 29. Cell viability on 5 colo-rectal carcinoma cell lines of ACV-TP-dG (protocol A). 
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The test showed a moderate cytotoxicity towards this kind of cells: the IC50s were between 
100 and 350 µM (Figure 29). These were the first interesting results on activity of the prodrug 
towards cancer cells.  
In order to verify if telomerase is involved in the activity of the prodrug, studies of base’s 
effect were made. It is known12 that the telomerase uses series of TTAGGG to build 
telomeres. This means that our prodrug should be hydrolyzed by telomerase releasing three 
cytotoxic compounds for every ACV-TP-dG, two for every ACV-TP-T and only one for 
ACV-TP-dA. The viability of the prodrugs ACV-TP-dA and ACV-TP-T (Figure 30) was 
measured using the same protocol. It is interesting to note that the activities of ACV-TP-dG 
and ACV-TP-T are  high in comparison with ACV-TP-dA. As expected, the prodrug toxicity 
follows the order indicated above with ACV-TP-dG and ACV-TP-dA being the most and the 
least toxic compounds respectively. 
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       Figure 30. Cell viability on SW620 colo-rectal carcinoma cell lines with 
       different TS groups (protocol A). 
 
 
Similar results were obtained using the protocol B and measuring both cell viability and 
proliferation (Figure 31). Moreover, if the TS group is not recognized by the telomerase, as in 
the case of ACV-TP-dC, the cytotoxicity is even lower. These results could be a prove of the 
involvement of telomerase on the prodrug’s activation. 
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Figure 31.  Cell viability and proliferation of the four ACV prodrugs on colo320 colo-rectal carcinoma cell line 
(protocol B). 
 
 
The tests show that the most active compound is ACV-TP-dG. Moreover, the activity 
measured in protocol B was higher than that in protocol A. These results pushed us to 
determine the activity of the prodrug within 52 hours. The cytotoxicity of ACV-TP-dG was 
compared with that of the 5-fluorouracil, an antimetabolite drug used in anticancer therapy. 
The test showed that the prodrug immediately stops the proliferation, but after a few hours the 
cells start growing again. On the other side 5-fluorouracil only showed activity after more 
than 24 hours (Figure 32). These different activities can be due to the different activity 
mechanisms of the two molecules. The 5-fluorouracile acts by an uptake into target cells, 
followed by an intracellular conversion to 5-fluorodeoxyuridine-5’monophosphate which 
covalently binds to thymidylate synthase, thereby blocking the synthesis of dTTP and hence 
the replication of DNA. For this reason the activity of 5-fluorouracil only showed after several 
hours. 
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Figure 32. Cell viability with respect to control during 52 hours of ACV-
TP-dG (100 µM) and 5-fluorouracil (5FU, 100 µM) on SW620 colo-
rectal carcinoma cell line.  
 
According to the activity mechanism supposed, the prodrug ACV-TP-dG should initially be 
hydrolyzed freeing the ACVDP, which is being transformed from a kinase into acyclovir 
triphosphate (ACVTP), and therefore incorporated in the DNA chain, thereby blocking its 
synthesis. The resistance shown towards the prodrug after 48 hours, could be due to DNA 
repair mechanisms normally active in the cells. 
It was therefore necessary to use protocol B in order to evaluate the highest cytotoxicity of the 
prodrug on different cell lines. 
Applying this protocol, the ACV-TP-dG was used on other cell lines to verify its activity on 
different kinds of tumors: SW620, SW480, colo320 and colo741 between colo-rectal 
carcinoma cell lines, HT1080 as fibroblastoma cell line and HeLa A1 for cervical cancer cell 
line. ACV-TP-dG was also tested on 18Co normal colon epithelial cell line. All these tests 
showed that the  cytoxicity of the prodrug is higher for cancer cells than for healthy ones, 
where the telomerase activity is not present (Figure 33). This is an important result, both 
because an anticancer drug must have low toxicity towards healthy cells and because it is 
another evidence that the telomerase is involved in the activity of prodrugs. 
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Figure 33.  IC50 on various cell lines of ACV-TP-dG (protocol B). 
 
 
It is important to note that, in order to be active, the prodrug needs to retain its original 
structure which allows it to cross the cellular membrane. Indeed, when we treated SW620 
cells with the fragments ACV-MP or ACV-DP, no activity was detected, thus indicating that 
the hydrolyzed fragments are not able to enter the cell. The addition of lipids is effective in 
helping the membrane crossing in the case of ACV-MP and ACV-DP, while the ACV-TP-
dG compound shows the same activity both in the presence and in the absence of lipids. This 
clearly indicates that the cytotoxicity of our prodrugs is due to its structural features that allow 
them to enter the cell and to release the active drug once inside, due to the telomerase activity 
(Figure 34). 
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                  Figure 34. Effect of liposome on cell viability of SW620 colo-rectal cancer  
                               line with different cytotoxic compounds (protocol A). 
 
 
3.3 Studies on different CT portion 
 
The change of the CT portion (ACV) maintaining the same TS (dG) fragment has also been 
tested. The toxicity of a series of compounds, ddC-TP-dG and AraC-TP-dG in addition to 
ACV-TP-dG, was analyzed obtaining similar results in terms of cell vitality (Figure 35), but 
interestingly better in terms of cell proliferation for AraC-TP-dG (Figure 36). This can be 
attributed to the fact that the CT of the new prodrug, AraC, is endowed with a different 
cytotoxic activity mechanism in comparison with ACV and ddC. In fact ACV and ddC are 
chain terminators while AraC is an antimetabolite agent that is able both to inhibit the 
ribonucleotide-reductase causing a lack of deoxynucleotide into the cell and to terminate the 
synthesis of DNA. Thus the cell is not able to synthesize new DNA, and the proliferation is 
then completely inhibited. 
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       Figure 35. Cell viability of colo 320 cells treated with prodrugs showing different  
CT moiety (protocol B) 
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          Figure 36. Cell proliferation of colo 320 cells treated with prodrugs showing different  
           CT moiety (protocol B). 
 
 
On the whole, the results obtained with prodrug ddC-TP-dG were quite similar to those 
obtained with ACV-TP-dG: this shows that, if the activity mechanism of the cytotoxic 
compound freed in the cell is the same, the cytotoxicity values are similar.  
Further tests made with AraC-TP-dG also showed, by and large, a noteworthy difference in 
the IC50 values, measured according to viability or proliferation (Figure 37). In particular, it 
seems clear that this molecule blocks cell proliferation more effectively if compared with the 
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other prodrugs synthesized and tested, rather than reducing its viability and hence causing its 
apoptosis. 
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Figure 37.  Values of IC50 measured with cell viability or proliferation in different cancer cell treated with 
AraC-TP-dG.  
 
Of particular relevance were the results obtained with pancreatic cancer cell lines (Panc1, 
IC50 = 1 µM), a kind of cell line which is particularly resistant to treatments with usual 
anticancer drugs. The results obtained with leukemia cell line were the only ones that had a 
good IC50 value with both methods, viability and proliferation.  
The IC50 values obtained by proliferation methods on the two cell lines HeLa showed an 
activity of the AraC-TP-dG molecule about 6-7 times higher in HeLa E1 cell line rather than 
in HeLa A1. The two lines differ from each other only because in HeLa E1 the telomerase 
activity is about 25 times higher than in HeLa A167. Hence, the fact that the prodrug is more 
active towards the first cell line can further confirm the activity mechanism of the prodrug. 
This interesting result with AraC-TP-dG prompted us to use this prodrug in tests on 
leukemia cell line in comparison with arabinocytosine (AraC). AraC is an antimetabolite 
agent used in antileukemia therapy. It is, at the moment, the most efficient drug used for this 
kind of disease, but has many side effects. 
The tests on HL60 leukemia cell line showed similar cytotoxicity for the two compounds. The 
results of the viability tests and proliferation test are shown in Figure 38. This result could be 
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of some importance if, together with a high antiproliferation activity, a lower toxicity in vivo 
with respect to AraC were detected. 
 
AraC
AraC-TP-dG
0 2 4 6 8 10 12 14 16 18 20
IC50(µM)
 proliferation
 viability
 
    Figure 38. Comparison between activity of AraC-TP-dG and AraC in HL60 
     leukemia cell line using viability and proliferation assays. 
 
 
3.4 Short summary 
 
According to the tests made so far, telomerase seems involved in the activity mechanism of 
the prodrug. This can be firstly proven by the fact that the ACV-TP-dC, when the TS group 
is 2’-deoxycytidine (i.e. the nucleoside which is not recognized by telomerase), shows very 
low toxicity (Figure 31). As a matter of fact if the compound were hydrolyzed by a DNA-
polymerase or by any phosphatase instead of by telomerase, the toxicity of the molecule 
would not depend on the type of TS group chosen, since these enzymes can indifferently use 
any nucleoside (dG, dA, dC or T) as substrates. 
Another positive sign is the lower toxicity of these molecules on healthy cells, even though 
the usual anticancer drugs are  normally more active towards cancer cells, because of their 
cellular activity, which is higher than in healthy cells. 
Even the different toxicity found in HeLa E1 and HeLa A1 cells (in HeLa E1 the telomerase 
activity is almost 25 times higher than in HeLa A1), treated with AraC-TP-dG prodrug, is an 
evidence that strengthen our hypothesis. 
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The functioning of the AraC-TP-dG prodrug is also interesting, since its anti-proliferative 
activity turns out to be very high towards all cell lines tested, with IC value lower than 5µM 
and therefore close to the value of the common anticancer agents (usually more toxic towards 
healthy cell). 
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4 MICE TESTS 
 
To complete the biological test, the prodrugs ACV-TP-dG and AraC-TP-dG were tested in 
vivo on mice in order to evaluate their toxicity and activity. These two molecules were chosen 
because of their more interesting IC50 values, as shown by the in vitro results. The prodrug 
ACV-TP-dG, in particular, turned out to be the most active towards tumors of the colo-rectal 
carcinoma cell line, while the results obtained with AraC-TP-dG on leukemia cell line were 
very interesting if compared with the AraC activity. 
 
 
4.1 Activity in vivo of ACV-TP-dG 
 
Preliminary tests on healthy mice showed a low acute and chronic toxicity: the LD50 in mice 
is between 4g/Kg and 8g/Kg, while mice chronically treated with the prodrug (two months, 3 
times per week) at a dose of  0,16 g/Kg survived and showed a phenotype of hair loss. Even if 
the hair loss is a characteristic of many anticancer drugs, it can be related to telomerase 
activity because it is active in hair follicles. 
The prodrug was tested on different mice with different kinds of tumor: two colo-rectal 
carcinoma human cell lines (colo320 and HT29), a synergic colo-rectal carcinoma cell line 
(CT26) and a melanoma synergic cell line (B16F10).  
The mice were treated at 10 mg/mouse every other day for a total of 10 times. 
In all mice the cytostatic effect on tumors measured was modest in comparison with control 
group as shown below (Figure 39-41). 
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Figure 39. Comparison between control (AV K) and treated with ACV-TP-dG (AV Tr)  starting from the same 
level of development nu/nu COLO320 human colo-rectal carcinoma (mean values/group) 
  
 
As reported in Figure 39, the tumor growth (COLO320, human colo-rectal carcinoma cell 
line) is only moderately slowed down by the prodrug administration (which starts from the 
same dimension of the tumor). The worst result was obtained using Balb/c CT26 colo-rectal 
carcinoma (Figure 40), and in one case an increase in tumor dimension was obtained with 
respect to control (Figure 41), as though the product was a stimulator for the tumor growth. 
The prodrug has therefore shown a modest activity only for the cell line where, according to 
in vitro tests, it turned out to be more active (colo320, Figure 39).  
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Figure 40. Comparison between control (AV K) and treated with ACV-TP-dG (AV TR)starting from the same 
level of development Balb/c CT26 colo-rectal carcinoma (mean values/group) 
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Figure 41. Comparison between control (AV K) and treated with ACV-TP-dG starting from the same level of 
development C57BL/6 B16F10 melanoma (mean values/group) 
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4.2 Activity in vivo of AraC-TP-dG 
 
To evaluate the activity of the prodrug AraC-TP-dG in vivo, the toxicity in healthy mice and 
the ability of molecule to suppress the growth of HL60 human cell in nude animals were 
examined and compared to AraC. 
To this purpose NOD/SCID mice were chosen. NOD/SCID mice are appropriate for this 
study because of their genetic immunodeficiency and their capability of tolerating the human 
leukemia cell inoculated.  
For toxicity studies, these mice were treated with two different doses of AraC and AraC-TP-
dG, as reported in Table 5, continuatively repeated for four days. Both concentrations used 
for the two drugs tested were equimolar. At the end of the treatment (after 3 weeks) all mice 
had survived.  
 
Groups Mice for groups Dose and administration 
Control 2 Physiological/i.p./4days 
AraC 2 200mg/Kg/i.p./4days 
AraC 2 800mg/Kg/i.p./4days 
AraC-TP-dG 2 400mg/Kg/i.p./4days 
AraC-TP-dG 2 1600mg/Kg/i.p./4days 
Table 5.  Summary scheme of the treatment made in NOD/SCID mice for the evaluation of pharmacological 
toxicity of AraC and AraC-TP-dG. 
 
On the whole, the results of the study on toxicity, comparing AraC-TP-dG with AraC, 
showed: 
- similar low toxicity in liver 
- similar toxicity in bone marrow  
- similar toxicity in kidney 
- lower toxicity of AraC-TP-dG on spleen.  
Thus, the tested prodrug has an in vitro effectiveness similar to that of AraC and a similar or 
lower toxicity especially at spleen level. 
Once the prodrug toxicity was evaluated, its pharmacological effectiveness in vivo towards 
leukemia was analyzed. To this purpose, NOD/SCID mice were inoculated with HL60 human  
leukemia cells and, after 7 days, were treated with intraperitoneal administration of 1g/Kg of 
AraC-TP-dG or of a physiological solution in the control group, continuatively  for 4 days. 
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The first important date for the evaluation of the disease progression was represented by 
FACS analysis, that was made by estimating the percentage of human leukemia cells with 
respect to the murine ones in the bone marrow and in peripheral blood of each mouse. 
The effect appears particularly evident in the bone marrow where the percentage of human 
leukemia cells was reduced by over an half in comparison to the control mice (Table 6). These 
results were similar for the mice treated with AraC. 
 
 
 Bone marrow Peripheral blood 
HL60 + physiological solution 5.3% 12% 
HL60 + AraC-TP-dG 2.2% 6.2% 
HL60 + AraC 3.25% 3.2% 
Table 6.  Percentage of human cells with respect to the murine ones in the bone marrow 
and in peripheral blood. 
 
 
With respect to control group the one treated with AraC-TP-dG shows a substantial 
reduction of bone marrow angiogenesis in those groups treated with the prodrug. The 
leukemia cells are able to increase the degree of bone marrow angiogenesis and hence an 
alteration of bone marrow functionality. The reduction of the degree of bone marrow 
angiogenesis implies a better functional bone marrow activity and a reduced capacity of 
leukemia cells to penetrate in tissue or to produce metastasis. 
Moreover, at spleen level, the prodrug treatment shows a clear reduction of leukemia cells. 
This reduction means that AraC-TP-dG is able to reduce the invasion of leukemia cells the 
outer bone marrow organs. 
These dates confirm therefore that the activity of AraC-TP-dG can be compared to the 
activity of AraC, even though the former shows a lower toxicity, especially at spleen level. 
The prodrug AraC-TP-dG was tested also in nu/nu mice inoculated with human colorectal 
carcinoma cell lines colo320. The mice were treated with intravenous administration 
(200mg/Kg every 3 day for 10 times) of AraC-TP-dG or of a physiological solution in the 
control group. The administration was started at the appearance of the tumor almost 16 mm2. 
During the treatment no side effects and no significant changes in body weight were observed. 
The AraC-TP-dG demonstrated a certain efficacy in reducing the growth of colo320 human 
colorectal carcinoma in nu/nu mice with this protocol (Figure 42).  
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Figure 42. Comparison between CONTROL and treated (TREAT) with AraC-TP-dG (200mg/Kg/i.v./day 
every 3 day). 
 
However, the treatment did not inhibit the metastatic spread. An autoptic control 
demonstrated liver metastases both in untreated and longer treated mice. 
Another group of nu/nu mice inoculated with human colorectal carcinoma cell lines colo320 
was treated with AraC-TP-dG daily with 500mg/Kg intracardiac. This high dosage produced 
occasional episodes of convulsions immediately after the administration. No reduction of 
tumor growth was shown with this protocol. On the contrary, a progressive toxicity was 
indicated by the reduction of body weight, by the reduced development of the animals 
(smaller than the controls), and by a quicker death than controls with hepatomegaly due to 
intense metastatic spread.  
 
4.3 Short summary 
 
The results obtained in vivo with AraC-TP-dG are encouraging, since they show a reduction 
of the disease progression in the mice inoculated  with leukemia cells HL60. Unlike our 
expectations, however, AraC-TP-dG is just as toxic as AraC. 
The AraC-TP-dG demonstrated a certain efficacy in reducing the growth of colo320 human 
colorectal carcinoma in nu/nu mice when the dose was low (4 mg), intermittent (every 3rd 
day) and prolonged. 
The ACV-TP-dG shows on the contrary low acute toxicity but also low anticancer activity 
toward mice inoculated with colorectal carcinoma cells colo320. 
  49
 
5 MATERIALS AND METHODS. 
 
5.1 Synthesis 
 
5.1.1 General Method 
 
1H-NMR, 13C-NMR and 31P-NMR were recorder on a Varian Gemini 200 (200 MHz, 50 MHz 
and 80 MHz respectively). Chemical shifts are quoted in ppm using residual solvent as 
internal standard except 31P chemical shifts are given relative to 85% H3PO4 (external 
standard, δp = 0.00 ppm).  
All purchased chemicals were used as received without further purification except POCl3 that 
was refluxed for 1 hour and than distilled. 
The reactions involving nucleotides were monitored by thin-layer chromatography (TLC) 
using PEI-cellulose F (Merck) and  chromatography was carried out on DEAE-cellulose fast 
flow (Sigma) . The other reaction were monitored by TLC using silica gel silice (Merck 60, 
70-230 mesh) and  flash chromatography was carried out on flash silica gel (Merck 60A, 230-
400 mesh). 
All air- and moisture-sensitive manipulations were carried out under a dry nitrogen 
atmosphere using standard Schlenk techniques. 
 
5.1.2 Synthesis of 2,3’-anhydro-5’-O-benzoyl-2’-deoxyuridine 13 
 
A solution containing 2’-deoxyurindine 12 (1.5g, 6.57 mmol) and triphenylphosphine (2.59g, 
9.86 mmol) in DMF (9 mL) was prepared, a solution comprised of diisopropyl 
azodicarboxylate (1.99g, 9.86 mmol) and benzoic acid (1.2g, 9.86 mmol) in DMF (4,5 mL) 
was added dropwise with stirring at room temperature and the reaction was allowed to 
HN
O
N
O
OBzO
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proceed for 20 min. An addiction aliquot of triphenylphosphine (2.59g, 9.86mmol) and 
diisopropyl azodicarboxylate (1.99g, 9.86 mmol) was added. The reaction was allowed to 
proceed for 1h, diethyl ether (80 mL) was added, and the mixture was stirred for 10 min at 
room temperature. The resulting suspension was cooled to ice-bath temperature, and the white 
crystalline precipitate was collected by filtration and washed with cold diethyl ether to give 
1.9g of the product 13 (yield 92%). 
1H-NMR (DMSO-d6, 200MHz) δ (ppm): 2.52-2.58 (m, 2H), 4.40-4.64 (m, 2H), 5.49 (br s, 
1H), 5.81 (d, J = 7.4 Hz, 1H), 6.00 (d, J = 3.8 Hz, 1H), 7.50-7.73 (m, 4H), 7.96 (d, J = 7.0 
Hz, 2H). 
13C-NMR (DMSO-d6, 50MHz) δ (ppm): 32.67, 62.47, 77.27, 81.87, 86.92, 107.88, 128.55, 
128.93, 129.06, 133.34, 140.57, 153.50, 165.14, 170.04. 
 
5.1.3  Synthesis of 3’-O-nitro-5’-O-benzoyl-2’-deoxyuridine 14 
 
 
A mixture containing  2,3’-anhydro-5’-O-benzoyl-2’-deoxyuridine 13 (1g, 3.18 mmol) and 
NH4OH (3.82 g, 47.75 mmol) in dry DMF (15 mL) was stirred at 110-120°C for 12 h under 
argon. The solvent was removed in vacuo, and the residue was purified via silica gel flash 
column chromatography using cyclohexane – Ethylacetate (1:2) as eluent to give the 
corresponding product 14 (390 mg, yield 32.5%). 
1H-NMR (DMSO-d6, 200MHz) δ (ppm): 2.56-2.74 (m, 2H), 4.48-4.64 (m, 3H), 5.59 (d, J = 
8HZ, 1H), 5.76 (m, 1H), 6.13 (t, J = 6.6 Hz, 1H), 7.50-7.55 (m, 2H), 7.65-7.73 (m, 2H), 7.99 
(d, J = 7.0 Hz, 2H), 11.42 (br s, 1H). 
13C-NMR (DMSO-d6, 50MHz) δ (ppm): 34.23, 64.03, 79.17, 83.29, 84.78, 102.06, 128.72, 
129.06, 129.15, 133.47, 140.44, 150.15, 162.77, 165.32. 
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5.1.4  Synthesis of 4-(1,2,4-triazolo)-4-deoxy-3’-O-nitro-5’-O-benzoyl-2’-
deoxyuridine 15 
                                                                                                                                                                         
4-Chlorophenyl dichlorophophate (174.42 mg, 0.71 mmol) and 1,2,4-triazole (98.08mg, 1.42 
mmol) was added to a solution of  3’-O-nitro-5’-O-benzoyl-2’-deoxyuridine 14 (268mg, 0.71 
mmol) in pyridine (2.7 mL) at 0°C with stirring. The reaction was allowed to proceed at 25°C 
for 4 days with stirring, and the solvent was removed in vacuo. The residue was dissolved in 
CH2Cl2 (30 mL), this solution was washed with water (2 x 10 mL) and NaHCO3 (1 x 10 mL). 
The organic fractions was dried on Na2SO4, and the solvent was removed in vacuo. 
Purification of the residue by flash silica gel column chromatography using 
cyclohexane:ethylacetate (1:5) gave 126 mg of the product 15 (yield 41%). 
1H-NMR (CDCl3, 200MHz) δ (ppm): 2.30-2.45 (m, 1H), 3.20 (ddd, J = 15.2, 5.8, 1.4 Hz, 
1H), 4.63 (dd, J = 11.6, 3.2Hz, 1H), 4.71 (dd, J = 5.2, 3.0 1H), 4.80 (dd, J = 11.6, 3.0 Hz, 
1H), 5.63 (d, J = 6.6 Hz, 1H), 6.20 (dd, J = 7.8, 6.0 Hz, 1H), 6.93 (d, J = 7.2 Hz, 2H), 7.34-
7.43 (m, 2H), 7.49-7.58 (m, 1H), 7.88-7.92 (m, 2H), 8.10 (s, 1H), 8.22 (d, J = 7.2 Hz, 1H), 
9.20 (s, 1H). 
13C-NMR (CDCl3, 50MHz) δ (ppm): 38.01, 63.58, 82.46, 82.78, 88.47, 94.74, 128.68, 128.77, 
129.34, 133.78, 143.18, 145.19, 153.88, 159.42, 165.72. 
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5.1.5 Synthesis of 3’-O-nitro-5’-O-benzoyl-2’-deoxycytidine 16 
 
A solution of 4-(1,2,4-triazolo)-4-deoxy-3’-O-nitro-5’-O-benzoyl-2’-deoxyuridine 15 (126 
mg, 0.29 mmol) in NH4OH/dioxane (1:3, 6.5 mL) was stirred at room temperature for 5 h 
prior to removal of the solvent in vacuo. The residue was purified via flash silica gel column 
chromatography using MeOH:CH2Cl2 (1:9) as eluent to give 54.8mg of the product 16 (yield 
50%). 
1H-NMR (CDCl3, 200MHz) δ (ppm): 2.26-2.40 (m, 1H), 2.88 (dd, J = 15, 5.8 Hz, 1H), 4.56-
4.66 (m, 3H), 5.58 (d, J = 6.6 Hz, 1H), 5.67 (d, J = 7.4 Hz, 1H), 6.15 (dd, J = 8.0, 5.8, 1H) 
7.41-7.63 (m, 4H), 7.98 (d, J = 8.4Hz, 2H), 8.23 (br s, 2H). 
13C-NMR (CDCl3, 50MHz) δ (ppm): 35.6, 64.20, 79.23, 83.77, 85.60, 94.30, 128.60, 129.10, 
133.34, 140.68, 154.60, 165.29, 165.48, 165.80. 
 
5.1.6 Synthesis of 3’-O-nitro-2’-deoxycytidine 17 
 
A solution 0.5 M of NaOMe in methanol (5.3 mL, 2.65 mmol) was added to 3’-O-nitro-5’-O-
benzoyl-2’-deoxycytidine 16 (1g, 2.65 mmol), and the mixture was stirred at room 
temperature for 15 min. The solvent was removed in vacuo. Purification of the residue by 
flash silica gel column chromatography using CHCl3:methanol (6:1) as eluent afforded 
460mg of the  product 17 (yield 63%). 
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1H-NMR (DMSO-d6, 200MHz) δ (ppm): 2.23-2.38 (m, 1H), 2.40-2.49 (m, 1H), 3.65-3.67 (m, 
2H), 4.20 (br s, 1H), 5.31 (br s, 1H), 5.59 (d, J = 6.2Hz, 1H), 5.77 (d, J = 7.4Hz, 1H), 6.15 
(dd, J = 8.8, 5.8Hz, 1H), 7.22 and 7.26 (two br s, 2H), 7.80 (d, J = 7.8 Hz, 2H). 
13C-NMR (DMSO-d6, 50MHz) δ (ppm): 35.87, 61.10, 82.78, 84.80, 85.00, 94.36, 141.70, 
152.34, 163.67. 
ESI-MS: calculated C9H13N4O6 (M – H) 273.09, observed 273.1 
5.1.7 Synthesis of mono-O-acetate ester of ganciclovir 22 
 
 
To a mixture of 1 g of ganciclovir (3.92 mmol), 900 µM of trimethyl orthoacetate (7 mmol) 
and 100 DMF was added 320 µM of trifluoroacetic acid (4.16 mmol) under stirring, and the 
mixture was stirred at room temperature overnight. The water (8 mL) was added and the 
solution was stirred for 6h at room temperature. The solvent was removed under vacuum. 
Purification of the residue by flash silica gel column chromatography using CH2Cl2:methanol 
(6:1) as eluent afforded 1.06 g of the  product 22 (yield 91%). 
1H-NMR (DMSO-d6, 200MHz) δ (ppm): 1.83 (s, 3H), 3.37-3.41(m, 2H), 3.77-3.91 (m, 2H), 
4.02-4.08 (m, 1H), 5.42 (s, 2H), 6.68 (br s, 2H), 7.83 (s, 1H), 10.91 (br s, 1H). 
13C-NMR (DMSO-d6, 50MHz) δ (ppm): 23.42, 60.30, 63.32, 71.41, 76.85, 116.35, 137.88, 
151.45, 154.01, 157.16, 173.53. 
 
5.1.8 Synthesis of 2-benzyloxyethanol monophosphate 23 
 
 
To a solution of 300 mg of POCl3 (2.5 mmol) in 2 mL of diethyl ether at 0°C were added  276 
mg (2 mmol) of 2-benzyloxyethanol 18. The mixture was allowed to warm to room 
temperature and was maintained under stirring for 12 hours. The solvent was removed under 
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vacuum and then 20 mL of  0°C cold water were added to the solution. The pH was adjust to 
9 with NaOH 2M solution. Then 10 mL of ethanol and 208 mg of BaCl2 (1 mmol) was added 
to the solution. The white precipitate was removed by filtration and the precipitate was 
washed with water/ethanol 1:1. The solution was evaporated to dryness obtaining 495 mg of 
23 as barium salt (70%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 3.71-3.76 (m, 2H), 3.87-3.94 (m, 2H), 4.61(s, 
2H), 7.43-7.47(m, 5H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): 3.95 (s). 
ESI-MS: calculated C9H12O5P (M – H) 231.05, observed 231.50. 
 
5.1.9 Synthesis of 2-((1H-benzo[d]imidazol-1-yl)methoxy)ethanol monophosphate 
24 
 
To a solution of 200 mg of POCl3 (1.3 mmol) in 1 mL of THF at 0°C were added 200 mg (1 
mmol) of  2-((1H-benzo[d]imidazol-1-yl)methoxy)ethanol 19. The mixture was allowed to 
warm to room temperature and was maintained under stirring for 12 hours. The solvent was 
removed under vacuum and 10 mL of water was added. The pH was adjust to 9 with NaOH 
2M and the solution was subjected to a reduction of volume (5 ml) and loaded on to a DEAE-
cellulose column. The column was eluted with linear gradient of triethylammonim 
bicarbonate (0.05-0.3M). Appropriate fractions were evaporated under vacuum. The residual 
bicarbonate was eliminated by two sequential evaporation steps from 5 ml methanol. 
Evaporation to dryness yielded 284 mg of 24 triethylammonium salt (0.6 mmol, yield = 60%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.23-1.30 (t, J = 7.32, 18H), 3.13-3.24 (q, J=7.32, 
12H), 3.84-3.87 (m, 2H), 6.00 (s, 2H), 7.66-7.73 (m, 2H), 7.85-7.89 (m, 1H), 7.95-7.99 (m, 
1H), 9.42 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): -0.27 (s). 
 
 
 
 
N
N
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-O
O
O-
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5.1.10 Synthesis of acyclovir monophosphate ACVMP 
 
 
A mixture of 1g acyclovir (4.3 mmol) and 6 ml triethylphosphate was gradually added to a 
mixture of 4 ml triethylphosphate and 860 µl phosphorus oxychloride (8.6 mmol) at  -10°C. 
The mixture was maintained at 0°C for 12 h under stirring. Then 100 ml of ice-cold 5% 
NaHCO3 in water were added to the solution. After stirring at 0°C for 1 h and at room 
temperature for 8 h, the pH was adjusted to 7.0 with NaOH 1M. After further 12 h under 
stirring, the mixture was extract with 3 x 50ml of diethyl ether and the water solution was 
evaporated to dryness, dissolved in the minimum volume of water and loaded onto a DEAE-
cellulose column. The column was eluted with a linear gradient (0.05-0.5 M) of 
triethylammonium bicarbonate, pH 7.5). Appropriate fractions were evaporated under 
vacuum. Methanol was added and evaporated again to remove triethylammonium bicarbonate 
obtaining ACVMP as triethylammonium salt (1.28 g, 2.53 mmol, yield = 59%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.17-1.21 (t, J = 7.3, 18H), 3.06-3.17 (q, J = 7.3, 
12H), 3.69-3.77 (m, 2H), 3.85-3.94 (m, 2H), 5.51(s, 1H), 7.93 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): 3.79 (s). 
ESI-MS: calculated C8H11N5O6P (M – H) 304.05, observed 304.30. 
5.1.11  Synthesis of mono-O-acetate ester of ganciclovir monophosphate GCVMP 
NH
N
N
O
NH2N
O
O
OP-O
O
O-
O  
The procedure described above for the synthesis of acyclovir monophosphate ACVMP was 
followed for the preparation of mono-O-acetate ester of ganciclovir monophosphate 
GCVMP, using mono-O-acetate ester of ganciclovir 22 (1 g, 3.57 mmol) instead of acyclovir, 
to give the product monophosphate as white solid (1.24 g, 2.14 mmol, yield = 60%). 
NH
N
N
O
NH2N
OOP
-O
O
O-
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1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.17-1.21 (t, J = 7.3 Hz, 18H), 3.06-3.17 (q, J = 
7.3  Hz, 12H), 3.48-3.81 (m, 5H), 5.54(s, 2H), 7.81 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): 4.10 (s). 
 
5.1.12 Synthesis of 3’-azidothymidine-5’-monophosphate AZTMP 
 
NH
O
ON
O
N3
OP-O
O-
O
 
 
 
The procedure described above for the synthesis of acyclovir monophosphate was followed 
for the preparation of 3’-azidothymidine-5’-monophosphate, using 3’azidothymidine (AZT, 
100 mg, 0.37 mmol) instead of acyclovir, to give 3’-azidothymidine-5’-monophosphate as 
white solid (90 mg, 0.15 mmol, yield = 40%). 
1H-NMR (D2O, pH 7.5, 200 MHz) δ (ppm): 1.23-1.30 (t, J = 7.3 Hz, 18H), 1.92 (s, 3H), 2.44-
2.52 (m, 2H), 3.13-3.24 (q, J=7.3 Hz, 12H), 3.96-4.00 (m, 2H), 4.12-4.20 (m, 1H), 4.46-4.54 
(m, 1H), 6.22-6.29 (t, J=6.6 Hz, 1H), 7.81 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): 2.57 (s). 
 
 
5.1.13 Synthesis of 2’,3’-dideoxycytidine-5’-monophosphate ddCMP 
N
NH2
ON
OOP
-O
O-
O
 
 
The procedure described above for the synthesis of acyclovir monophosphate was followed 
for the preparation of 2’,3’-dideoxycytidine-5’-monophosphate, using 2’3’-dideoxycytidine 
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(ddC, 100 mg, 0.47 mmol) instead of acyclovir, to give 2’3’-dideoxycytidine-5’-
monophosphate as white solid (145 mg, 0.28 mmol, yield = 59%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.23-1.30 (t, J = 7.3 Hz, 18H), 1.74-2.11 (m, 2H), 
2.24-2.40 (m, 2H), 3.13-3.24 (q, J=7.3 Hz, 12H), 3.85-3.90 (m, 1H), 4.02-4.11 (m, 1H), 4.18-
4.30 (m, 1H), 5.88-5.92 (m, 1H), 6.04-6.08 (d, J=7.3 Hz, 1H), 8.08-8.12 (d, J=7.3 Hz, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): 1.30 (s). 
 
5.1.14 Synthesis of 3’-O-nitro-2’-deoxycytidine-5’-monophosphate 25. 
 
NH
NH2
ON
O
ONO2
OP
O
O-
-O
 
 
The procedure described above for the synthesis of GCVMP was followed for the preparation 
of 3’-O-nitro-2’-deoxycytidine-5’-monophosphate 25, using 3’-O-nitro-2’-deoxycytidine 17 
(450 mg, 1.63 mmol) instead of 22, to give the product monophosphate as white solid (190 
mg, 0.34 mmol, yield = 21%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.17-1.21 (t, J = 7.3, 18H), 2.25-2.50 (m (2H), 
3.06-3.17 (q, J = 7.3, 12H), 3.48-3.81 (m, 5H), 5.54(s, 2H), 7.81 (s, 1H). 3.65-4.20 (m, 4H), 
5.65 (d, J = 6.2Hz, 1H), 6.15 (m, 1H), 7.80 (d, J = 6.2 Hz, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): 4.55 (s). 
 
5.1.15 Synthesis of arabinocytosine-5’-monophosphate AraCMP 
NH
NH2
ON
O
OH
OP
O
O-
-O
OH
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The procedure described above for the synthesis of acyclovir monophosphate ACVMP was 
followed for the preparation of arabinocytosine-5’-monophosphate AraCMP, using 
arabinocyotisine AraC (1 mg, 4.11 mmol) instead of 22, to give the product monophosphate 
as white solid (1.08 g, 2.05 mmol, yield = 50%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.17-1.21 (t, J = 7.3, 18H), 3.06-3.17 (q, J = 7.3, 
12H), 3.99-4.07 (m, 2H), 4.19-4.23 (m, 1H), 4.36 (t, J = 5.13Hz, 2H), 6.05 (d, J = 7.3, 1H), 
6.17 (d, J = 5.13, 1H), 7.94 (d, J = 7.3 Hz, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): 3.80 (s). 
 
5.1.16 Synthesis of 2-benzyloxyethanol diphosphate 29 
OOPO
O
O-
P-O
O
O-  
The tributylammonium orthophosphate, necessary for this transformation, was prepared as 
follows. Anhydrous orthophosphoric acid (5 g, 51 mmol) and 10 ml of CH2Cl2 were put in a 
Schlenk tube, under anhydrous condition. Tributylamine (12.25 ml, 51 mmol) was then added 
dropwise into the solution in 30 minutes. The mixture was left under stirring for 1 h. CH2Cl2 
was evaporated and the reaction residue re-evaporated with 3 x 10ml anhydrous pyridine and 
2 x 10ml of anhydrous DMF. The final product was dissolved in anhydrous DMF to a 
concentration of 1M, and stored over molecular sieves (4Å) at 4°C. 
The barium salt of 23 (450mg, 1.6 mmol) was converted into its pyridinium salt using Dowex 
50W-X8 (pyridinium form resin). The column was eluted with 50% aqueous methanol. The 
eluted was evaporated under reduced pressure to dryness, and then 10 ml methanol and 760 µl 
tributylamine (3.2 mmol) were added. After 30 minutes stirring, the solution was concentrated 
under vacuum. The residue was dried by repeated addition and evaporation of anhydrous 
pyridine (3 x 10ml), anhydrous toluene (1 x 10ml) and anhydrous DMF (2 x 10 ml). 
The resulting tributylammonium salt of 23 was dissolved in 15 ml anhydrous DMF. 
1,1’-Carbonyldiimidazole (1 g, 8 mmol) was dissolved in 3.5 ml DMF. This solution was 
added to the solution of 23. The mixture was stirred at room temperature on molecular sieve. 
After 12 hours, 466 µl anhydrous methanol (8 mmol), and after further 30 minutes, 8 ml 1M 
tributylammonium orthophosphate in DMF (8 mmol) were added dropwise under stirring. 
After 12 h at room temperature, the precipitate was removed by centrifugation. The 
supernatant solution was added with 75 ml water and the resulting solution was extract with 3 
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x 50ml CHCl3, subjected to a reduction of volume (5 ml) and loaded on to a DEAE-cellulose 
column. The column was eluted with linear gradient of triethylammonim bicarbonate (0.05-
1M). Appropriate fractions were evaporated under vacuum. The residual bicarbonate was 
eliminated by two sequential evaporation steps from 20 ml methanol. Evaporation to dryness 
yielded 747 mg of 29 triethylammonium salt (1.21 mmol, yield = 76%). 
1H-NMR (D2O, pH 8.5, 200MHz) δ (ppm): 3.63 (t, J=4.4 Hz, 2H), 3.91-4.03 (m, 2H), 4.47 (s, 
2H), 7.30 (s, 5H). 
31P-NMR (D2O, pH 8.5, 80MHz) δ (ppm): -6.16 (d, J=22.0 Hz), -10.40 (d, J=22.0 Hz). 
ESI-MS: calculated C9H13O8P2 (M – H) 311.02, observed 311.50. 
5.1.17 Synthesis of 2’-deoxyguanosine-5’-diphosphate dGDP 
NH
N
N
O
NH2N
O
OH
OPO
O
O-
P
O
-O
O-
 
 
The procedure described above for 29 was followed for the preparation of 2’-deoxyguaosine-
5’-diphosphate (dGDP) using 2’-deoxyguanosine-5’-monophosphate triethylammonium salt 
(867 mg, 2.5 mmol) instead of 23, to give dGDP as white solid (654 mg, 1.02 mmol, yield = 
40%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.23-1.30 (t, J = 7.32, 27H), 2.53-2.65 (m, 1H), 
2.70-2.87 (m, 1H), 3.13-3.24 (q, J=7.32, 18H), 4.08-4.15 (m, 2H), 4.25-4.32 (m, 1H), 4.66-
4.73 (m, 1H), 6.35 (t, J = 6.59, 1H), 8.48 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80 MHz) δ (ppm): -6.64 (d, J = 23.2Hz), -10.90 (d, J = 23.19Hz). 
ESI-MS: calculated C10H14N5O10P2 (M – H) 426.02, observed 426.30. 
5.1.18 Synthesis of acyclovir diphosphate ACVDP 
 
NH
N
N
O
NH2N
OOPO
O
O-
P-O
O
O-  
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The procedure described above for 29 was followed for the preparation of acyclovir 
diphosphate (ACVDP) using acyclovir monophosphate triethylammonium salt (1.01 g 2 
mmol) instead of 23, to give ACVDP as white solid (984 mg, 1.42 mmol, yield = 70%). 
1H-NMR (D2O, pH 8.5, 200MHz) δ (ppm): 1.23-1.30 (t, J = 7.3 Hz, 27H), 3.14-3.25 (q, J = 
7.3 Hz, 18H), 3.77-3.81 (m, 2H), 4.04-4.12 (m, 2H), 5.56 (s, 1H), 7.98 (s, 1H). 
31P-NMR (D2O, pH 8.5, 80MHz) δ (ppm): -6.50 (d, J = 22.1), -10.77 (d, J = 22.1). 
ESI-MS: calculated C8H12N5O9P2 (M - H) 384.01, observed 384.20. 
5.1.19 Synthesis of 2’3’-dideoxycytidine-5’-diphosphate ddCDP 
 
-O P
O
O-
O P
O
O
O-
N
NH2
ON
O
 
 
The procedure described above for 29 was followed for the preparation of 2’,3’-
dideoxycytidine-5’-diphosphate (ddCDP) using 2’3’-dideoxycytidine-5’-monophosphate 
triethylammonium salt (105 mg, 0.2 mmol) instead of 23, to give ddCDP as white solid 
(100mg, 0.14 mmol, yield = 70%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.23-1.30 (t, J = 7.32, 18H), 1.62-1.96 (m, 2H), 
2.12-2.37 (m, 2H), 3.13-3.24 (q, J=7.32, 12H), 3.75-3.80 (m, 1H), 3.92-4.02 (m, 1H), 4.11-
4.21 (m, 1H), 5.85-5.88 (m, 2H), 7.81-7.85 (d, J=7.32, 1H). 
31P-NMR (D2O, pH 7.5, 80 MHz) δ (ppm): -4.51:-6.47 (br s), -8.40:-9.40 (br s). 
 
5.1.20 Synthesis of arabinocytosine-5’-diphosphate AraCDP 
 
NH
NH2
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O
OH
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O
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P
O
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-O
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The procedure described above for 29 was followed for the preparation of arabinocytosine-5’-
diphosphate (AraCDP) using arabinocytosine-5’-monophosphate triethylammonium salt 
(1.08g, 2 mmol) instead of 23, to give AraCDP as white solid (900 mg, 1.25 mmol, yield = 
62.5%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.23-1.30 (t, J = 7.32, 27H), 3.13-3.24 (q, J=7.32, 
18H), 3.98-4.07 (m, 1H), 4.13-4.26 (m, 3H), 4.34-4.42 (m, 1H), 6.01-6.10 (br d, J = 6.70, 
1H), 6.18 (d, J = 5.86 Hz, 1H), 7.86 (d, J = 5.86 Hz, 1H). 
31P-NMR (D2O, pH 7.5, 80 MHz) δ (ppm): -6.01 (d, J = 21.9 Hz), -10.51 (d, J = 21.9 Hz). 
 
5.1.21 Synthesis of 2-benzyloxyethanoyl 2’-deoxy-5’-guanosyltriphosphate Ph-TP-
dG 
NH
N
N
O
NH2N
O
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O
O-
P
O
O-
OP
O
O
O-
O
 
The tributylammonium salt of dGMP and 29 were prepared by first converting their sodium 
salt or triethylammonium salt in pyridinium salt by chromatography on a Dowex 50W-X8 
column. 
A solution of water (5 ml) and 714 mg of dGMP (2 mmol) was loaded onto a Dowex 50W-
X8 (pyridinium form). The column was eluted with 50% aqueous methanol. The eluent was 
evaporated under reduced pressure to dryness, and then 464 µl of tributylamine (2 mmol) and 
10 ml water were added. After 30 minutes the mixture was evaporated to dryness. The 
resulting residue was subjected to 3 x 10 ml evaporation from anhydrous pyridine and 2 x 5ml 
evaporation from anhydrous DMF. 
550 mg of 29 triethylammonium salt (1 mmol) was dissolved in 10 ml water loaded on a 
Dowex 50W-X8 column and eluted with water/methanol (1:1). The solution was concentrated 
under vacuum, and then 500 µl tributylamine (2 mmol) and 10 ml water/methanol (1:1) were 
added. After 30 minutes under stirring the reaction mixture was evaporate to dryness, the 
residue was dried by repeated addition and evaporation of anhydrous pyridine (3 x 7.5 ml) 
and anhydrous DMF (2 x 7.5 mL). 
The anhydrous tributylammonium salt of 29, 10 ml DMF and 800 mg 1,1’-
carbonyldiimidazole (5 mmol) in 5 mL of DMF were mixed in a Schlenk tube under 
anhydrous conditions. After 2h stirring at room temperature on molecular sieves, 400 µl 
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methanol (7 mmol) and 30 minutes later the anhydrous tributylammonium salt of dGMP in 
14 ml of DMF were added. After additional 14 h stirring, the precipitate of the reaction 
mixture was removed by centrifugation. At the solution was added 100 mL of water and 
extracted with CHCl3 (3 x 50mL). Then the water solution was evaporated to dryness, 
dissolved in minimal volume of water and loaded on DEAE-cellulose column. The column 
was eluted with linear gradient (0.05-0.5M) of triethylammonium bicarbonate buffer (pH 7.5). 
Ph-TP-dG-containing fractions were pooled and concentrated to dryness. The residual 
bicarbonate was eliminated by two sequential evaporations from 20 ml methanol, and the 
residual material was converted into its sodium salt using Dowex 50W-X8 resin, after 
converting the latter from its H+ form to its sodium form by washing with four bed volumes 
of NaOH 1M, then washing with water until pH neutrality. The resulting preparation was 
dried under vacuum to a dry yellow powder (200 mg, 0.83 mmol, yield = 28%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 2.36-2.47 (m, 1H), 2.61-2.75 (m, 1H), 3.67 (t, J = 
4.40 Hz, 2H), 4.05-4.21 (m, 5H), 4.44 (s, 2H), 4.65-4.71 (m, 1H), 6.18 (t, J = 6.59, 1H), 7.27-
7.37 (m, 4H), 8.05 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): -10.95 (d, J = 18.31Hz), -11.29 (d, J=18.31), -
22.75 (t, J = 18.31Hz). 
 
5.1.22 Synthesis of Acycloguanosyl 2’-deoxy-5’-guanosyltriphosphate ACV-TP-dG 
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The procedure described above for Ph-TP-dG was followed for the preparation of ACV-TP-
dG using 2’-deoxyguanosine-5’-monophosphate disodium salt (dGMP, 1 g, 2.8 mmol) and 
ACVDP tributylammonium salt (194 mg, 0.28 mmol) instead of 29, to give ACV-TP-dG 
sodium salt as yellow powder (650 mg, 0.83 mmol, yield = 59%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 2.35-2.48 (m, 1H), 2.65-2.79 (m, 1H), 3.70-3.74 
(m, 2H), 4.05-4.20 (m, 5H), 4.65-4.71 (m, 1H), 5.39 (s, 1H), 6.16-6.23 (t, J = 6.6 Hz, 1H) 
7.84 (s, 1H), 7.99 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): -11.25 (d, J=19.5 Hz), -11.35 (d, J = 19.5), -
23.13(t, J = 19.5 Hz). 
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ESI-MS: calculated C18H24N10O15P3(M - H) 713.6, observed 713.20. 
 
5.1.23 Synthesis of Acycloguanosyl 2’-deoxy-5’-adenosyltriphosphate ACV-TP-dA 
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The procedure described above for Ph-TP-dG was followed for the preparation of ACV-TP-
dA using 2’-deoxyadenosine-5’-monophosphate disodium salt (dAMP, 165 mg, 0.5 mmol) 
instead of dGMP and ACVDP tributylammonium salt (194 mg, 0.28 mmol) instead of 29, to 
give ACV-TP-dA sodium salt as yellow powder (82 mg, 0.11 mmol, yield = 39%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 2.42-2.53 (m, 1H), 2.62-2.75 (m, 1H), 3.61-3.65 
(m, 2H), 3.97-4.19 (m, 5H), 4.64-4.71 (m, 1H), 5.29 (s, 1H), 6.31-6.38 (t, J = 6.6 Hz, 1H) 
7.70 (s, 1H), 8.05 (s, 1H), 8.34 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): -11.53 (d, J = 19.5 Hz), -11.71 (d, J=19.5 Hz), -
23.52 (t, J = 19.5 Hz). 
 
5.1.24 Synthesis of Acycloguanosyl 5’-thymidyltriphosphate ACV-TP-T 
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The procedure described above for Ph-TP-dG was followed for the preparation of ACV-TP-
T using thymidine-5’-monophosphate disodium salt (TMP, 183 mg, 0.5 mmol) instead of 
dGMP and ACVDP tributylammonium salt (194 mg, 0.28 mmol) instead of 29, to give 
ACV-TP-T sodium salt as yellow powder (100 mg, 0.13 mmol, yield = 46%). 
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1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.95 (s, 3H), 2.31-2.40 (m, 1H), 3.83-3.89 (m, 
2H), 4.12-4.29 (m, 5H), 4.61-4.68 (m, 1H), 5.59 (s, 1H), 6.31-6.38 (t, J = 6.59, 1H), 7.66 (s, 
1H), 7.79 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): -11.30:-11.64 (d, J=19.50), -11.59:-11.83 (d, 
J=19.50), -23.32: -23.80 (t, J=19.50). 
5.1.25 Synthesis of Acycloguanosyl 5’-cythydyltriphosphate ACV-TP-dC 
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The procedure described above for Ph-TP-dG was followed for the preparation of ACV-TP-
dC using 2’-deoxycythidine-5’-monophosphate disodium salt (dCMP, 76 mg, 0.25 mmol) 
instead of dGMP and ACVDP tributylammonium salt (87 mg, 0.14 mmol) instead of 29, to 
give ACV-TP-dC sodium salt as yellow powder (41 mg, 0.13 mmol, yield = 39%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 2.13-2.26 (m, 1H), 2.30-2.42 (m, 1H), 3.75 (br t, J 
= 4.39 Hz, 2H), 4.05-4.15 (m, 5H), 4.50-4.55 (m, 1H), 5.48 (s, 2H), 5.97 (d, J = 7.32Hz, 1H), 
6.21 (t, J = 6.59, 1H), 7.81 (d, J = 7.32 Hz, 2H), 7.88 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): -11.16 (d, J = 19.53 Hz), -11.35 (d, J = 18.31 Hz), 
-22.91 (dd, J= 19.53, 18.31 Hz). 
 
5.1.26 Synthesis of Acycloguanosyl-3’-azidothymidine-5’-triphosphate ACV-TP-
AZT 
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The procedure described above for Ph-TP-dG was followed for the preparation of ACV-TP-
AZT using 3’-azidothymidine-5’-monophosphate triethyammonium salt (AZTMP, 90 mg, 
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0.16 mmol) instead of dGMP and ACVDP tributylammonium salt (80 mg, 0.12 mmol) 
instead of 29, to give ACV-TP-AZT sodium salt as yellow powder (30 mg, 0.04 mmol, yield 
= 33%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.91 (s, 3H), 2.36-2.52 (m, 2H), 3.72-3.83 (m, 
2H), 4.05-4.24 (m, 4H), 4.52-4.63 (m, 1H), 5.43 (s, 2H), 6.27 (t, J = 7.3 Hz, 1H), 7.75 (s, 1H), 
7.88 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): -11.50 (d, J=18.3 Hz), -11.89 (d, J=18.3 Hz), -
23.33 (t, J = 18.3 Hz). 
 
5.1.27 Synthesis of 2’,3’-dideoxycytidine-2’-deoxy-5’-guanosyltriphosphate ACV-
TP-ddC 
 
NH
N
N
O
NH2N
O
OH
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O
O-
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O-
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O-
N
NH2
O N
O
 
 
The procedure described above for Ph-TP-dG was followed for the preparation of ddC-T-
PdG using 2’,3’-dideoxycytidine-5’-diphosphate triethylammonium salt (ddCDP, 100 mg, 
0.14 mmol) instead of 29 triethylammonium salt, and 2’deoxyguanosine-5’-monophosphate 
disodium salt (dGMP, 98 mg, 0.28 mmol), to give ddC-TP-dG sodium salt as yellow powder 
(20 mg, 0.04 mmol, yield = 28%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 1.74-2.11 (m, 2H), 2.35-2.75 (m, 4H), 3.70-3.85 
(m, 2H), 3.92-4.02 (m, 1H), 4.11-4.21 (m, 2H), 4.52-4.63 (m, 1H), 5.50 (s, 2H), 6.06-6.27 (m, 
2H), 7.85 (d, J=7.3 Hz, 1H), 7.95 (s, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): -11.25 (d, J=18.3, 2P), -22.75 (t, J=18.3 Hz). 
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5.1.28 Synthesis of arabinocythydyl 2’-deoxy-5’-guanosyltriphosphate AraC-TP-dG 
NH
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O
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O
O-
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O N
O P O
O-
O
O
OH
OH
P
O-
O
 
The procedure described above for Ph-TP-dG was followed for the preparation of AraC-TP-
dG using 2’-deoxyguanosine-5’-monophosphate disodium salt (dGMP, 1.45 g, 4.76 mmol) 
and AraCDP tributylammonium salt (1.54 g, 2.4 mmol) instead of 29, to give AraC-TP-dG 
sodium salt as yellow powder (760 mg, 0.95 mmol, yield = 39.6%). 
1H-NMR (D2O, pH 7.5, 200MHz) δ (ppm): 2.19-2.31 (m, 1H), 2.38-2.51 (m, 1H), 3.58-3.65 
(m, 1H), 3.94-4.10 (m, 6H), 4.45-4.50 (m, 2H), 5.96 (t, 1H), 6.05-6.10 (m, 1H), 7.78 (s, 1H), 
7.85-7.90(m, 1H). 
31P-NMR (D2O, pH 7.5, 80MHz) δ (ppm): -11.32 (d, J = 18.31 Hz, 2P), -22.84 (dd, J = 18.31 
Hz, 1P). 
 
 
5.2 Biological tests 
 
 
5.2.1 Cell Cultures. 
 
The human cell lines used in the study, SW480 colon carcinoma cells, their relative lymph 
node metastatic SW620 cells were obtained from the European Collection of Cell Cultures 
(ECACC), COLO320DMF colon carcinoma cells, COLO741 metastatic colon carcinoma 
cells, HT1080 human fibrosarcoma cells, RKO colon carcinoma cells were obtained from 
National Institute for Cancer Research (ICLC), CCD-18Co normal colon cell lines were 
obtained from ATCC, HeLa A1 cervical cancer cells were obtained from Swiss Institute for 
Experimental Cancer Research (ISREC), HL60 Human acute promyelocytic leukemia cells 
from Department of Experimental Pathology and Oncology of Florence. SW480, SW620, 
HT1080, RKO, COLO741 cells were grown in RPMI 1640 medium with L-glutamine (2 
mM), 10% FCS, penicillin (100.000 units/liter), streptomycin (100 mg/liter), COLO320DMF, 
HeLa A1 in DMEM medium with L-glutamine (2 mM), 10% FCS, penicillin (100.000 
units/liter), streptomycin (100 mg/liter), CCD-18Co in EMEM medium medium with NEAA 
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(0.1 mM), L-glutamine (2 mM), 10% FCS, penicillin (100.000 units/liter), streptomycin (100 
mg/liter).  Cells cultures were maintained at 37° C in a humid atmosphere of 5% CO2 and 
95% air. Cells were grown until 60-70 % confluence, and the experiments performed after 4-8 
passages. 
 
 
5.2.2 Analysis of cell proliferation and viability  
 
Normal and tumour cells were seeded in 96 well plates at a 15000 cells/well density, 24 h 
after seeding medium was changed and the prodrugs was added for additional 24 h. Cell 
viability was assessed measuring intracellular ATP content using Promega CellTiter-Glo® 
Luminescent Cell Viability Assay. The experiment was run according to manufacturer 
protocol, luminescence was recorded with a Wallac multiplate reader (Perkin-Elmer). Cell 
proliferation was assessed measuring BrdU incorporation in DNA synthesis (Cell 
proliferation ELISA, BrdU, Roche). BrdU was added to each well 6 h before the end of the 
experiment. The assay was run according to manufacturer protocol luminescence was 
recorded with a Wallac multiplate reader (Perkin-Elmer). 
 
5.2.3 Mice tests 
 
Animal studies for ACV-TP-dG and AraC-TP-dG on nu/nu (nude mice), Balb/c e C57BL/6 
mice were carried out at the Academy of Science of the Czech Republic, Division of 
Immunology and Gnotobiology. The studies of AraC-TP-dG on NOD/SCID mice (nude mice) 
were carried out in Florence at the Department of Experimental Pathology and Oncology. 
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6.1 Prodrugs activated by RNA-dependent DNA-polymerases, and their 
therapeutic uses. 
Bertini, Ivano; Luchinat, Claudio; Quattrone, Alessandro; Calamante, Massimo;        
Mordini, Alessandro 
     
    Publication number: WO200613203 
    Application number: WO2005EP53765 20050802  
 
Herein described are prodrugs activated by RNA-dependent DNA-polymerases, such as 
telomerase and retroviral reverse transcriptases, and their use for the preparation of 
pharmaceutical compositions, to be used for the treatment of solid tumours, of haematological 
tumors, of precancerous states and of diseases caused by infection with retroviruses. 
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6.2 A New Class of Cytotoxic Prodrugs. Synthesis and in vitro Evaluation 
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A New Class of Cytotoxic Prodrugs. Synthesis and in vitro Evaluation 
Ivano Bertini,*a,b Massimo Calamante,a,c Claudio Luchinat,a,d Alessandro Mordini,e Alessandro 
Provenzani,a,f and Alessandro Quattronea,d 
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A library of acyclovir-containing  triphosphates has been 
designed and synthesized aiming at a selective release of the 
cytotoxic agent inside tumor cells. 10 
Introduction 
It is well known that the nucleoside analogue acyclovir (9-(2-
hydroxyethoxymethyl)guanine, ACV (1), and its related 
compounds, owe their pharmacological anti-herpetic activity to a 
phosphorylation process which takes place in virally infected cells1. 15 
This phosphorylation is catalyzed by a herpes-specific thymidine 
kinase activity. The resulting monophosphate derivative (ACV-
MP) is toxic to human cells, as it is further phosphorylated by 
cellular kinases to the diphosphate (ACV-DP) and then the 
triphosphate (ACV-TP). The latter is incorporated into DNA by 20 
DNA polymerases and acts as a chain terminator leading to death 
of the virus-infected cell. ACV itself is of course able to penetrate 
the cell membrane, while ACV-MP, ACV-DP and ACV-TP are 
not, due to their higher charge2, so that they must be produced 
inside the cell. 25 
While the selective exploitation of a viral activity to generate the 
toxic phosphorylated ACV derivatives in situ makes ACV itself a 
very successful antiviral drug, it occurred to us that the toxic 
potential of ACV-MP, ACV-DP or ACV-TP could also be 
exploited to target other diseases – such as cancer – if one could 30 
base their production in situ not on a kinase-dependent 
phosphorylation but on a hydrolysis of a phosphorylated, inactive 
prodrug. We therefore conceived a class of molecules constituted 
by ACV (or any of its analogues) attached to a nucleoside 
triphosphate NU-TP (2). 35 
Such molecules should be more easily internalized in cells than the 
free ACV mono- di- and triphosphates due to the presence of a 
base moiety at each end, and should be easily hydrolyzed by 
enzymes such as phosphatases, DNA polymerases and telomerases, 
yielding primarily ACV-MP or ACV-DP. All these enzyme 40 
activities are lower in most normal cells than in cancer cells, or 
even absent.3,8 With these premises, we faced the problem of 
accessing a small library of molecules with general formula (2). 
Synthesis of triphosphates (2). 
All the triphosphates of general formula (2) have been prepared 45 
according to the same experimental procedure. The ACV-DP was 
prepared in two steps by a first chemical phosphorylation with 
POCl34,5 ,  in triethylphosphate at 0 °C to give the corresponding 
phosphorodichloridrate which is then hydrolyzed and eluted 
through a DEAE-cellulose column with triethylammonium 50 
bicarbonate in order to obtain the ACV-MP as triethylammonium 
salt. 
Scheme 1. Synthesis  of triphosphate (2) 
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The latter was then transformed into the tributylammonium salt by 
elution through a Dowex 50W-X8 (pyridinium form resin), 55 
followed by treatment with tributylammine in methanol/water (1:1)  
and then further phosphorylated with tributylammonium 
ortophosphate in the presence of 1,1’-carbonyldiimidazole to afford 
ACV-DP5,6. Finally, the tributylammonium salt of the resulting 
ACV-DP was condensed7  with the NU-monophosphate (usually 60 
commercially available) in DMF, again using 1,1’-
carbonyldiimidazole as the activator5,6.  
All the reactions were carried out using the tributylammonium salt, 
while the purifications was performed on a DEAE-cellulose 
column with a triethylammonium bicarbonate solution to give the 65 
corresponding phosphates as triethylammonium salts. All the final 
compounds were then converted into the corresponding sodium 
salts by elution through a Dowex 50W-X8 (sodium form resin). 
Table 1 contains all the substrates synthesized and tested so far.  
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Table 1a Nucleoside triphosphate-acyclovir derivatives produced in 
the present research. 
 
Entry Nu-MP2 ACV-TP-NU (yield) 
   
1 dG-MP ACV-TP-dG (59%) 
2 dA-MP ACV-TP-dA (39%) 
3 T-MP ACV-TP-T (46%) 
4 dC-MP ACV-TP-dC (39%) 
aACV= acyclovir, ACV-DP has been prepared in 41% yield; 2dG= 2’-
deoxyguanosine; dA= 2’-deoxyadenosine; T= thymidine; dC= 2’-75 
deoxycytidine; MP= monophosphate; DP= diphosphate; TP= triphosphate; 
all monophosphate are commercially available 
Biological activity of triphosphates (2) 
It is important to note first that in order to be active, the prodrug 
needs to retain its original structure which allows it to cross the cell 80 
membrane. Indeed when we treated SW620 cells (colon rectal 
carcinoma cells) with the fragments ACV-MP or ACV-DP, no 
toxicity was detected, indicating that the hydrolyzed fragments are 
not able to enter the cell. Addition of lipids is effective in helping 
the membrane crossing in the case of ACV-MP and ACV-DP, 85 
while the ACV-TP-NU compounds show the same toxicity both in 
the presence and in the absence of lipids. This clearly indicates that 
the cytotoxicity of our prodrugs is due to their structural features 
that allow them to enter the cell and to release the active drug once 
inside. 90 
 
 
Fig.1  (A) SW620 colo-rectal carcinoma cells tested with ACV-TP-dG; (B) 
Control SW620 colo-rectal carcinoma cells . 
All compounds in our library were then tested on cell coltures of 95 
different colo-rectal carcinoma cell lines, showing a slower growth 
of cells treated with the prodrug (Fig. 1A) in comparison with the 
control experiments (i.e. not treated cells, Fig. 1B). 
Figures 2A and 2B show the results in term of vitality and 
proliferation (see supporting material) of COLO320 cells (colo-100 
rectal carcinoma) when  submitted to treatment with the prodrugs 
constituted by acyclovir and 2’-deoxyguanosine (dG), 2’-
deoxyadenosine (dA), thymidine (T) and 2’-deoxycytidine (dC)  as 
the NU fragment. It is quite evident that all the prodrugs tested 
show toxicity against cancer cells, and it is interesting to note that 105 
the activity at high (1 mM) concentration is related to the group NU 
used, according to the following order: dG > T > dA > dC.  
 
Fig.2  Cellular vitality (A) and proliferation (B) of COLO320 cells using 
different NU groups.  Cellular vitality at different concentration  of prodrug 110 
ACV-TP-dG in healty cell line and 3 cancer cells line. A) 18Co: normal 
colon epithelial cell line; b) COLO320: metastatic colorectal tumor cell line; 
c) SW480: colorectal tumor cell line; d) SW620: metastatic colorectal tumor 
cell line. 
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Prodrug ACV-TP-dG was then tested on a series of cell coltures of 
different cancer types of colo-rectal carcinoma and normal colon 
epithelial cell line, showing that its cytotoxicity is higher for  cancer 
A
C
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cells than healthy ones by about an order of magnitude at 300 µM 
concentration (Fig. 2C). This suggests that the release of the active 120 
substance may indeed be due to one or more enzyme activities that 
are higher in such cells. 
The present experimental results suggest that the activity of the 
prodrugs follows the order which should be expected if telomerase 
was the active enzyme in the process. Telomerase uses series of 125 
TTAGGG to build telomeres8. Therefore, at each cycle, telomerase 
should release three cytotoxic compounds in the case of ACV-TP-
dG, two for ACV-TP-T, only one for ACV-TP-dA and none for 
ACV-TP-dC. Most somatic human cells do not produce 
telomerase, which is on the contrary highly expressed in cancer 130 
cells. While a telomerase contribution to the toxicity of the present 
prodrugs to cancer cells is an attractive possibility, its quantitation 
should await further experimental work and is outside the scope of 
the present research. 
Conclusions 135 
We have designed and synthesized a small library of acyclovir 
containing triphosphates aiming at the development of new active 
prodrugs. The latter are selectively toxic against cancer cells, thus 
showing that i) the newly designed molecules can penetrate the cell 
membrane and that ii) the drug is selectively liberated in cells 140 
affected by cancer. These findings hold promises towards a new 
approach in the therapeutic treatment of tumors.  
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7 Conclusions  
A new approach in the therapeutic treatment of tumors based on telomerase activity of cancer 
cells has been attempted. A library of triphosphate prodrugs recognized by telomerase 
enzymes has been synthesized and the activity of all compounds tested with cellular coltures 
of different cancer types showing promising activity. Every compound tested exhibits toxicity 
on the cancer cell lines used. Several evidences, particularly the cytotoxicity of the prodrugs 
with the same CT portions and different TS groups (Figure 31), the results with healthy cells 
(Figure 33) and the results with HeLa cell lines (Figure 37) support our hypothesis. 
The tests with liposome gave unexpected results. The high charge of our prodrugs should 
prevent them to cross the cellular membrane thus decreasing their toxicity. We have seen 
instead similar value both with liposome and without liposome. This means that the molecule 
can pass through the cellular membrane without aid of liposome probably due to an active 
transport mechanism. On the other hand we have found that the monophosphate or 
diphosphate of the cytotoxic compound can not cross the cellular membrane without 
liposome. This is important because it shows that if the prodrug is hydrolized out of the cell it 
cannot be toxic without liposome. 
All these evidences are in agreement with our hypothesis. The prodrug can cross the 
membrane of tumor cells and it is then recognized by the telomerase which hydrolizes it into 
2’-deoxyguanosine monophosphate and the diphosphate bound to the molecule that is 
responsible for the cytotoxicity of the drug. Despite this positive evidence, no test allowed us 
to get a molecular proof validating our hypotheses. It cannot therefore be excluded that also 
DNA-polymerase and phosphatase (not only telomerase) are involved in hydrolysis of the 
prodrug. A further step of the present work can be the development of an analytic method that 
could help finding the missing molecular proof.  
The modification of triphosphate leads indeed to a more toxic AraC-TP-dG compound, thus 
showing that more active prodrugs can be obtained by a careful choice of new cytotoxic 
portion CT. Moreover this compound showed an in vivo activity towards leukemia which can 
be compared with the antileukemia drugs AraC. The next step is to increase the activity of 
these compounds changing, for example, the CT portions. 
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